Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7292   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years

    Summary
    EudraCT number
    		 2022-003456-13
    Trial protocol
    		 Outside EU/EEA  
    Global end of trial date
    14 Dec 2020

    Results information
    Results version number
    		 v2(current)
    This version publication date
    09 Mar 2024
    First version publication date
    26 Jan 2023
    Other versions
    		 v1
    Version creation reason

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    DEN-313
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT02948829
    WHO universal trial number (UTN)
    		 U1111-1184-1893
    Sponsors
    Sponsor organisation name
    Takeda Vaccines, Inc
    Sponsor organisation address
    40 Landsdowne Street, Cambridge, United States, MA 02139
    Public contact
    Study Director, Takeda, TrialDisclosures@takeda.com
    Scientific contact
    Study Director, Takeda, TrialDisclosures@takeda.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Dec 2020
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    14 Dec 2020
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The purpose of this study is to assess the cellular immune responses following 2 doses given 3 months apart of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.
    Protection of trial subjects
    Study participants signed an Informed Consent Form. Assent is also obtained from the study participant where required.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    03 Apr 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Panama: 100
    Country: Number of subjects enrolled
    Philippines: 100
    Worldwide total number of subjects
    200
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    190
    Adolescents (12-17 years)
    10
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Participants took part in the study at 2 investigative sites in Panama and Philippines from 03 April 2017 to 14 December 2020.

    Pre-assignment
    Screening details
    		 Healthy participants were enroled in a single arm in this study to receive 2 doses of Tetravalent Dengue Vaccine (TDV) injection subcutaneously (SC).

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Arm title
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Arm description
    		 TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).
    Arm type
    		 Experimental

    Investigational medicinal product name
    Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Investigational medicinal product code
    TAK-003
    Other name
    Pharmaceutical forms
    Powder and solution for solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    TDV SC injection.

    Number of subjects in period 1
    		Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Started
    200
    Completed
    184
    Not completed
    16
         Other
    8
         Pregnancy
    1
         Withdrawal by Subject
    5
         Lost to follow-up
    2

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Reporting group description
    		 TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).

    Reporting group values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL Total
    Number of subjects
    		 200
    Age Categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 6.7 ( 2.28 ) -
    Gender categorical
    Units: Subjects
        Male
    		 99 99
        Female
    		 101 101
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    		 99 99
        Not Hispanic or Latino
    		 101 101
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    		 76 76
        Asian
    		 100 100
        Black or African American
    		 8 8
        White
    		 9 9
        More than one race
    		 7 7
    Baseline Seropositivity Status
    Seropositive at Baseline was defined as a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4.
    Units: Subjects
        Seropositive
    		 113 113
        Seronegative
    		 87 87
    Height
    Units: Cm
        arithmetic mean (standard deviation)
    		 118.38 ( 14.564 ) -
    Weight
    Units: Kg
        arithmetic mean (standard deviation)
    		 23.54 ( 10.258 ) -
    Body Mass Index (BMI)
    BMI = weight (kg)/[height (m)^2]
    Units: Kg/m^2
        arithmetic mean (standard deviation)
    		 16.15 ( 3.104 ) -
    Subject analysis sets

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: Panama
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seropositive
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seropositive at Baseline.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seronegative
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seronegative status at Baseline.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD4+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): CD4+ T cells.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD8+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): CD8+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Panama: CD4+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD4+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Philippines: CD4+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD4+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Panama: CD8+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.

    Subject analysis set title
    TDV 0.5 ml: Philippines: CD8+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Seropositive: CD4+ T-Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seropositive at Baseline, CD4+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Seronegative: CD4+ T-Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seronegative at Baseline, CD4+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Seropositive: CD8+ T- Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seropositive at Baseline, CD8+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Seronegative: CD8+ T-Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seronegative at Baseline, CD8+ T cells.

    Subject analysis sets values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL: Panama Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seropositive Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seronegative Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD4+ T Cells Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD8+ T Cells TDV 0.5 mL: Panama: CD4+ T Cells TDV 0.5 mL: Philippines: CD4+ T Cells TDV 0.5 mL: Panama: CD8+ T Cells TDV 0.5 ml: Philippines: CD8+ T Cells TDV 0.5 mL: Seropositive: CD4+ T-Cells TDV 0.5 mL: Seronegative: CD4+ T-Cells TDV 0.5 mL: Seropositive: CD8+ T- Cells TDV 0.5 mL: Seronegative: CD8+ T-Cells
    Number of subjects
    97
    98
    109
    86
    79
    79
    33
    46
    33
    46
    44
    35
    44
    35
    Age Categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    0 ( )
    0 ( )
    0 ( )
    0 ( )
    Gender categorical
    Units: Subjects
        Male
    0
    0
    0
    0
        Female
    0
    0
    0
    0
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    0
    0
    0
    0
        Not Hispanic or Latino
    0
    0
    0
    0
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0
    0
    0
    0
        Asian
    0
    0
    0
    0
        Black or African American
    0
    0
    0
    0
        White
    0
    0
    0
    0
        More than one race
    0
    0
    0
    0
    Baseline Seropositivity Status
    Seropositive at Baseline was defined as a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4.
    Units: Subjects
        Seropositive
    0
    0
    0
    0
        Seronegative
    0
    0
    0
    0
    Height
    Units: Cm
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    0 ( )
    0 ( )
    0 ( )
    0 ( )
    Weight
    Units: Kg
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    0 ( )
    0 ( )
    0 ( )
    0 ( )
    Body Mass Index (BMI)
    BMI = weight (kg)/[height (m)^2]
    Units: Kg/m^2
        arithmetic mean (standard deviation)
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    ( )
    0 ( )
    0 ( )
    0 ( )
    0 ( )

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Reporting group description
    		 TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: Panama
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seropositive
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seropositive at Baseline.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seronegative
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seronegative status at Baseline.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD4+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): CD4+ T cells.

    Subject analysis set title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD8+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): CD8+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Panama: CD4+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD4+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Philippines: CD4+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD4+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Panama: CD8+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Panama, CD8+ T cells.

    Subject analysis set title
    TDV 0.5 ml: Philippines: CD8+ T Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants from Philippines, CD8+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Seropositive: CD4+ T-Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seropositive at Baseline, CD4+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Seronegative: CD4+ T-Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seronegative at Baseline, CD4+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Seropositive: CD8+ T- Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seropositive at Baseline, CD8+ T cells.

    Subject analysis set title
    TDV 0.5 mL: Seronegative: CD8+ T-Cells
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3): Participants seronegative at Baseline, CD8+ T cells.

    Primary: Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination

    		 Close Top of page
    End point title
    		 Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination [1]
    End point description
    Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural proteins (NS) NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentage of participants with cellular immune response were reported. Percentages are rounded off to the nearest decimal point. Per-Protocol Set (PPS) included all participants from the Full Analysis Set (FAS) who have no major protocol violations. Participants analysed are participants with data available for analysis.
    End point type
    Primary
    End point timeframe
    1 month post second vaccination (Day 120)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was performed for this outcome measure.
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    173
    Units: percentage of participants
        number (confidence interval 95%)
    97.1 (93.4 to 99.1)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3

    		 Close Top of page
    End point title
    		 Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
    End point description
    Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentages are rounded off to the nearest decimal point. PPS included all participants from the FAS who have no major protocol violations. Number analysed is the number of participants with data available for analysis at the given timepoint.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Day 270); Years 1, 2 and 3
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    195
    Units: percentage of participants
    number (confidence interval 95%)
        Day 30 (n=171)
    95.3 (91.0 to 98.0)
        Day 90 (n=183)
    95.1 (90.9 to 97.7)
        Day 270 (n=173)
    95.4 (91.1 to 98.0)
        Year 1 (n=174)
    90.8 (85.5 to 94.7)
        Year 2 (n=150)
    84.0 (77.1 to 89.5)
        Year 3 (n=171)
    77.8 (70.8 to 83.8)
    No statistical analyses for this end point

    Secondary: Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination

    		 Close Top of page
    End point title
    		 Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination
    End point description
    The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. PPS included all participants from the FAS who have no major protocol violations. Participants analysed are participants with data available for analysis.
    End point type
    Secondary
    End point timeframe
    1 month post second vaccination (Day 120)
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    168
    Units: SFC/million PBMCs
        median (inter-quartile range (Q1-Q3))
    846.5 (378.5 to 1968.5)
    No statistical analyses for this end point

    Secondary: Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3

    		 Close Top of page
    End point title
    		 Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3
    End point description
    The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. PPS included all participants from the FAS who have no major protocol violations. Number analysed is the number of participants with data available for analysis at the given timepoint.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Days 120 and 270); Years 1, 2 and 3
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    195
    Units: SFC/million PBMCs
    median (inter-quartile range (Q1-Q3))
        Day 30 (n=163)
    1019.0 (418.0 to 2542.0)
        Day 90 (n=174)
    536.5 (254.0 to 1212.0)
        Day 270 (n=165)
    486.0 (203.0 to 1252.0)
        Year 1 (n=158)
    193.0 (76.0 to 482.0)
        Year 2 (n=126)
    104.0 (41.0 to 560.0)
        Year 3 (n=133)
    136.0 (47.0 to 577.0)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country

    		 Close Top of page
    End point title
    		 Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country
    End point description
    Percentage of participants with cellular immune response by country (Panama and Philippines) were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). Percentages are rounded off to the nearest decimal point. PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analysed is the number of participants with data available for analysis at the given timepoint.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90) 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, 3
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL: Panama Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
    Number of subjects analysed
    97
    98
    Units: percentage of participants
    number (confidence interval 95%)
        Day 30 (n=76,95)
    96.1 (88.9 to 99.2)
    94.7 (88.1 to 98.3)
        Day 90 (n=85,98)
    96.5 (90.0 to 99.3)
    93.9 (87.1 to 97.7)
        Day 120 (n-75,98)
    97.3 (90.7 to 99.7)
    96.9 (91.3 to 99.4)
        Day 270 (n=75,98)
    94.7 (86.9 to 98.5)
    95.9 (89.9 to 98.9)
        Year 1 (n=83,91)
    91.6 (83.4 to 96.5)
    90.1 (82.1 to 95.4)
        Year 2 (n=52,98)
    86.5 (74.2 to 94.4)
    82.7 (73.7 to 89.6)
        Year 3 (n=79,92)
    79.7 (69.2 to 88.0)
    76.1 (66.1 to 84.4)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status

    		 Close Top of page
    End point title
    		 Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status
    End point description
    Percentage of participants with cellular immune response by dengue Baseline seropositivity status (Seropositive and Seronegative) were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1[M0]) and >=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1,DENV-2,DENV-3 and DENV-4 and NS1 for DENV-2. PPS ‘by Baseline seropositivity status’ included all participants from the FAS who have no major protocol violations. Number analysed is the number of participants with data available for analysis at the given timepoint.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seropositive Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seronegative
    Number of subjects analysed
    109
    86
    Units: percentage of participants
    number (confidence interval 95%)
        Day 30 (n= 97,74)
    91.8 (84.4 to 96.4)
    100.0 (95.1 to 100.0)
        Day 90 (n=104,79)
    93.3 (86.6 to 97.3)
    97.5 (91.2 to 99.7)
        Day 120 (n=100,73)
    96.0 (90.1 to 98.9)
    98.6 (92.6 to 100.0)
        Day 270 (n=101,72)
    93.1 (86.2 to 97.2)
    98.6 (92.5 to 100.0)
        Year 1 (n=98,76)
    87.8 (79.6 to 93.5)
    94.7 (87.1 to 98.5)
        Year 2 (n=93,57)
    80.6 (71.1 to 88.1)
    89.5 (78.5 to 96.0)
        Year 3 (n=97,74)
    74.2 (64.3 to 82.6)
    82.4 (71.8 to 90.3)
    No statistical analyses for this end point

    Secondary: Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country

    		 Close Top of page
    End point title
    		 Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country
    End point description
    The magnitude of cellular immune response by country (Panama and Philippines) was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analysed is the number of participants with data available at the given timepoint.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL: Panama Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines
    Number of subjects analysed
    97
    98
    Units: SFC/million PBMCs
    median (inter-quartile range (Q1-Q3))
        Day 30 (n=73,90)
    1019.0 (437.0 to 2228.0)
    1065.0 (418.0 to 2546.0)
        Day 90 (n=82,92)
    531.5 (252.0 to 1116.0)
    577.5 (255.5 to 1396.0)
        Day 120 (n=73,95)
    780.0 (322.0 to 1525.0)
    1003.0 (437.0 to 2304.0)
        Day 270 (n=71,94)
    426.0 (184.0 to 1382.0)
    512.5 (210.0 to 1130.0)
        Year 1 (n=76,82)
    209.0 (81.5 to 494.0)
    178.5 (73.0 to 451.0)
        Year 2 (n=45,81)
    76.0 (45.0 to 229.0)
    124.0 (41.0 to 615.0)
        Year 3 (n=63,70)
    147.0 (51.0 to 280.0)
    117.0 (43.0 to 659.0)
    No statistical analyses for this end point

    Secondary: Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status

    		 Close Top of page
    End point title
    		 Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status
    End point description
    The magnitude of cellular immune response by dengue Baseline seropositivity status (Seropositive and Seronegative) was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response:IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline:a reciprocal neutralizing titer >=10 for one or more dengue serotypes. Seronegative at Baseline:having a reciprocal neutralizing titer <10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analysed:participants with data available for analysis at given time point.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seropositive Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seronegative
    Number of subjects analysed
    109
    86
    Units: SFC/million PBMCs
    median (inter-quartile range (Q1-Q3))
        Day 30 (n=89,74)
    1415.0 (529.0 to 3302.0)
    840.5 (379.0 to 1844.0)
        Day 90 (n=97,77)
    743.0 (257.0 to 1560.0)
    473.0 (246.0 to 927.0)
        Day 120 (n=96,72)
    1086.0 (429.0 to 2521.0)
    700.0 (343.0 to 1476.0)
        Day 270 (n=94,71)
    592.0 (184.0 to 1569.0)
    400.0 (225.0 to 808.0)
        Year 1 (n=86,72)
    275.0 (105.0 to 690.0)
    132.0 (69.0 to 247.0)
        Year 2 (n=75,51)
    135.0 (46.0 to 615.0)
    74.0 (38.0 to 304.0)
        Year 3 (n=72,61)
    180.0 (61.0 to 645.5)
    103.0 (35.0 to 430.0)
    No statistical analyses for this end point

    Secondary: Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age

    		 Close Top of page
    End point title
    		 Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age
    End point description
    The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. SFC/million PBMC for any peptide pool is reported in participants >10 years of age. The analysis of samples collected at Day 90 and annually at Years 1, 2 and 3 for outcome measures related to assessment of the cellular immune response is still ongoing because of the limited testing capacities of the laboratory due to COVID-19; the data will be reported when available.
    End point type
    Secondary
    End point timeframe
    Day 14
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    7
    Units: SFC/million PBMC
        median (inter-quartile range (Q1-Q3))
    227.0 (124.0 to 3781.0)
    No statistical analyses for this end point

    Secondary: Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3

    		 Close Top of page
    End point title
    		 Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3
    End point description
    The phenotype characterization of cellular immune response was assessed by intracellular cytokine staining (ICS) by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells). ICS Subset 'by T-cells' included participants from PPS who have IFN-γ ELISPOT responses >500 SFC/million PBMCs and availability of sufficient cells. Number analysed is the number of participants with data available for analysis for specific category.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD4+ T Cells Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD8+ T Cells
    Number of subjects analysed
    79
    79
    Units: percentage of T cells
    median (inter-quartile range (Q1-Q3))
        IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30 (n=71,71)
    0.008260 (0.003050 to 0.020000)
    0.001350 (0.000000 to 0.008190)
        IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30 (n=71,71)
    0.005110 (0.001953 to 0.010000)
    0.020000 (0.002580 to 0.039350)
        IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30 (n=71,71)
    0.005380 (0.002430 to 0.009420)
    0.015580 (0.003084 to 0.043000)
        IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30 (n=71,71)
    0.000000 (0.000000 to 0.001350)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30 (n=71,71)
    0.000000 (0.000000 to 0.000130)
    0.001210 (0.000000 to 0.003000)
        IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30 (n=71,71)
    0.000000 (0.000000 to 0.000120)
    0.001610 (0.000000 to 0.004370)
        IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30 (n=71,71)
    0.003720 (0.000580 to 0.006770)
    0.018180 (0.000190 to 0.054000)
        IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30 (n=71,71)
    0.002810 (0.000130 to 0.006420)
    0.140000 (0.058000 to 0.448100)
        IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30 (n=71,71)
    0.002890 (0.000020 to 0.006240)
    0.140790 (0.028940 to 0.382000)
        IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30 (n=71,71)
    0.002310 (0.000000 to 0.007080)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30 (n=71,71)
    0.002110 (0.000000 to 0.007290)
    0.000000 (0.000000 to 0.000760)
        IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30 (n=71,71)
    0.003350 (0.000000 to 0.008360)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30 (n=71,71)
    0.000850 (0.000000 to 0.004190)
    0.007490 (0.002150 to 0.032580)
        IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30 (n=71,71)
    0.000000 (0.000000 to 0.002890)
    0.061520 (0.025260 to 0.208580)
        IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30 (n=71,71)
    0.000498 (0.000000 to 0.003520)
    0.063490 (0.020000 to 0.222230)
        IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30 (n=71,71)
    0.001000 (0.000000 to 0.009000)
    0.002000 (0.000000 to 0.008000)
        IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30 (n=71,71)
    0.000000 (0.000000 to 0.007000)
    0.000000 (0.000000 to 0.008000)
        IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30 (n=71,71)
    0.000000 (0.000000 to 0.010000)
    0.001700 (0.000000 to 0.010000)
        IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30 (n=71,71)
    0.000000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.013000)
        IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30 (n=71,71)
    0.010000 (0.000000 to 0.040000)
    0.012000 (0.000000 to 0.030000)
        IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30 (n=71,71)
    0.010000 (0.000000 to 0.050000)
    0.008000 (0.000000 to 0.030000)
        IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90 (n=72,72)
    0.003825 (0.001215 to 0.009130)
    0.000000 (0.000000 to 0.004075)
        IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90 (n=72,72)
    0.002908 (0.000285 to 0.006325)
    0.005565 (0.001470 to 0.012500)
        IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90 (n=72,72)
    0.002050 (0.000000 to 0.005690)
    0.004020 (0.000622 to 0.013000)
        IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90 (n=72,72)
    0.000615 (0.000000 to 0.001460)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.002200)
    0.000000 (0.000000 to 0.001566)
        IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.000980)
    0.000000 (0.000000 to 0.001865)
        IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90 (n=72,72)
    0.001045 (0.000000 to 0.002805)
    0.005155 (0.000020 to 0.021160)
        IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90 (n=72,72)
    0.001608 (0.000000 to 0.003055)
    0.106350 (0.032245 to 0.198546)
        IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90 (n=72,72)
    0.000750 (0.000000 to 0.002583)
    0.076145 (0.017500 to 0.156850)
        IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90 (n=72,72)
    0.001050 (0.000000 to 0.008000)
    0.000000 (0.000000 to 0.000884)
        IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90 (n=72,72)
    0.000910 (0.000000 to 0.003360)
    0.000000 (0.000000 to 0.000340)
        IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90 (n=72,72)
    0.002925 (0.000000 to 0.006000)
    0.000000 (0.000000 to 0.000374)
        IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.001425)
    0.001820 (0.000000 to 0.006305)
        IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.000973)
    0.022310 (0.007580 to 0.075184)
        IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.001251)
    0.021455 (0.002945 to 0.045665)
        IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.009000)
    0.001500 (0.000000 to 0.010000)
        IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.009000)
        IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90 (n=72,72)
    0.003000 (0.000000 to 0.010500)
    0.000000 (0.000000 to 0.010000)
        IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.009500)
        IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90 (n=72,72)
    0.000000 (0.000000 to 0.028500)
    0.012000 (0.000500 to 0.032470)
        IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90 (n=72,72)
    0.009500 (0.000000 to 0.050000)
    0.008500 (0.000000 to 0.026500)
        IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120 (n=75,75)
    0.008340 (0.003340 to 0.017000)
    0.001320 (0.000000 to 0.004240)
        IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120 (n=75,75)
    0.003410 (0.001041 to 0.007190)
    0.010000 (0.002650 to 0.018000)
        IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120 (n=75,75)
    0.002100 (0.000000 to 0.004710)
    0.007850 (0.002230 to 0.027000)
        IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120 (n=75,75)
    0.001050 (0.000000 to 0.002420)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120 (n=75,75)
    0.000000 (0.000000 to 0.001420)
    0.000000 (0.000000 to 0.001800)
        IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120 (n=75,75)
    0.000000 (0.000000 to 0.000935)
    0.000960 (0.000000 to 0.002340)
        IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120 (n=75,75)
    0.002110 (0.000000 to 0.005070)
    0.007340 (0.000000 to 029850)
        IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120 (n=75,75)
    0.002000 (0.000000 to 0.004160)
    0.116110 (0.047000 to 0.317000)
        IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120 (n=75,75)
    0.000860 (0.000000 to 0.002820)
    0.096230 (0.030050 to 0.207090)
        IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120 (n=75,75)
    0.007160 (0.002000 to 0.015040)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120 (n= 75,75)
    0.000000 (0.000000 to 0.004710)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120 (n=75,75)
    0.003350 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120 (n=75,75)
    0.002070 (0.000000 to 0.005030)
    0.004080 (0.000000 to 0.011000)
        IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120 (n=75,75)
    0.000990 (0.000000 to 0.002630)
    0.038000 (0.013270 to 0.094810)
        IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120 (n=75,75)
    0.000000 (0.000000 to 0.002480)
    0.018850 (0.007000 to 0.060560)
        IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120 (n=75,75)
    0.009000 (0.000000 to 0.014000)
    0.002000 (0.000000 to 0.014000)
        IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120 (n=75,75)
    0.001000 (0.000000 to 0.010000)
    0.001000 (0.000000 to 0.017000)
        IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120 (n=75,75)
    0.000000 (0.000000 to 0.013000)
    0.001000 (0.000000 to 0.015000)
        IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120 (n=75,75)
    0.002000 (0.000000 to 0.028000)
    0.004000 (0.000000 to 0.020000)
        IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120 (n=75,75)
    0.000000 (0.000000 to 0.030000)
    0.012000 (0.000000 to 0.028000)
        IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120 (n=75,75)
    0.020000 (0.000000 to 0.050000)
    0.012000 (0.000000 to 0.030000)
        IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270 (n=71,71)
    0.006150 (0.002940 to 0.015000)
    0.000000 (0.000000 to 0.002450)
        IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270 (n=71,71)
    0.002520 (0.000050 to 0.006570)
    0.004630 (0.001430 to 0.010157)
        IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270 (n=71,71)
    0.002840 (0.000220 to 0.005230)
    0.004430 (0.000955 to .019000)
        IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.000980)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001830)
        IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001470)
        IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270 (n=71,71)
    0.001100 (0.000000 to 0.003380)
    0.004620 (0.000000 to 0.023950)
        IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270 (n=71,71)
    0.001210 (0.000000 to 0.003450)
    0.089000 (0.033000 to 0.213910)
        IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270 (n=71,71)
    0.000334 (0.000000 to 0.002500)
    0.067000 (0.021000 to 0.197960)
        IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270 (n=71,71)
    0.004010 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.004830)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270 (n=71,71)
    0.001630 (0.000000 to 0.005000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.002570)
    0.003060 (0.000000 to 0.008450)
        IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.001720)
    0.015360 (0.002440 to 0.029940)
        IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.002320)
    0.013000 (0.002000 to 0.029600)
        IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270 (n=71,71)
    0.001000 (0.000000 to 0.008000)
    0.001000 (0.000000 to 0.007000)
        IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.001980)
    0.000000 (0.000000 to 0.005000)
        IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.007000)
    0.000000 (0.000000 to 0.006000)
        IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.014000)
    0.002000 (0.000000 to 0.018000)
        IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270 (n=71,71)
    0.005000 (0.000000 to 0.030000)
    0.015000 (0.000000 to 0.044000)
        IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270 (n=71,71)
    0.000000 (0.000000 to 0.050000)
    0.014000 (0.000000 to 0.033000)
        IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1 (n=70,70)
    0.003980 (0.000000 to 0.007470)
    0.000000 (0.000000 to 0.001410)
        IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1 (n=70,70)
    0.001998 (0.000000 to 0.005000)
    0.001360 (0.000000 to 0.003970)
        IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1 (n=70,70)
    0.001275 (0.000000 to 0.005900)
    0.001600 (0.000000 to 0.006660)
        IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1 (n=70,70)
    0.000105 (0.000000 to 0.001700)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1 (n=70,70)
    0.000000 (0.000000 to 0.001240)
    0.000000 (0.000000 to 0.001120)
        IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1 (n=70,70)
    0.000000 (0.000000 to 0.001370)
    0.000000 (0.000000 to 0.000828)
        IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1 (n=70,70)
    0.001085 (0.000000 to 0.003000)
    0.000000 (0.000000 to 0.012000)
        IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1 (n=70,70)
    0.001100 (0.000000 to 0.002718)
    0.022915 (0.004790 to 0.054750)
        IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1 (n=70,70)
    0.000856 (0.000000 to 0.003000)
    0.022135 (0.002010 to 0.069860)
        IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1 (n=70,70)
    0.003000 (0.000000 to 0.009125)
    0.000000 (0.000000 to 0.001130)
        IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1 (n=70,70)
    0.001585 (0.000000 to 0.005470)
    0.000000 (0.000000 to 0.000968)
        IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1 (n=70,70)
    0.003545 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.001370)
        IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1 (n=70,70)
    0.000587 (0.000000 to 0.002580)
    0.000434 (0.000000 to 0.005200)
        IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1 (n=70,70)
    0.000000 (0.000000 to 0.002000)
    0.003075 (0.000000 to 0.010870)
        IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1 (n=70,70)
    0.000000 (0.000000 to 0.001880)
    0.003400 (0.000000 to 0.016640)
        IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1 (n=70,70)
    0.000000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.009000)
        IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1 (n=70,70)
    0.000500 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.008000)
        IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1 (n=70,70)
    0.003500 (0.000000 to 0.018000)
    0.000000 (0.000000 to 0.010000)
        IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1 (n=70,70)
    0.002500 (0.000000 to 0.060000)
    0.000000 (0.000000 to 0.007000)
        IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1 (n=70,70)
    0.000000 (0.000000 to 0.070000)
    0.005210 (0.000000 to 0.022000)
        IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1 (n=70,70)
    0.042500 (0.000000 to 0.120000)
    0.007000 (0.000000 to 0.020250)
        IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2 (n=56,56)
    0.002920 (0.000140 to 0.006890)
    0.000000 (0.000000 to 0.001050)
        IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2 (n=56,56)
    0.000727 (0.000000 to 0.003915)
    0.001925 (0.000000 to 0.004043)
        IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2 (n=56,56)
    0.001500 (0.000000 to 0.005815)
    0.001535 (0.000000 to 0.005245)
        IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2 (n=56,56)
    0.000000 (0.000000 to 0.001040)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2 (n=56,56)
    0.000000 (0.000000 to 0.000853)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2 (n=56,56)
    0.000000 (0.000000 to 0.001435)
    0.000000 (0.000000 to 0.000982)
        IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2 (n=56,56)
    0.000871 (0.000000 to 0.002065)
    0.001015 (0.000000 to 0.004355)
        IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2 (n=56,56)
    0.000080 (0.000000 to 0.001760)
    0.014120 (0.004700 to 0.059078)
        IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2 (n=56,56)
    0.000810 (0.000000 to 0.002310)
    0.013923 (0.002940 to 0.052000)
        IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2 (n=56,56)
    0.001000 (0.000000 to 0.005000)
    0.000100 (0.000000 to 0.001980)
        IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2 (n=56,56)
    0.000000 (0.000000 to 0.003405)
    0.003625 (0.001660 to 0.007235)
        IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2 (n=56,56)
    0.002835 (0.000000 to 0.009205)
    0.002915 (0.000000 to 0.008730)
        IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2 (n=56,56)
    0.000420 (0.000000 to 0.002115)
    0.000100 (0.000000 to 0.001980)
        IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2 (n=56,56)
    0.000210 (0.000000 to 0.001285)
    0.003625 (0.001660 to 0.007235)
        IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2 (n=56,56)
    0.000150 (0.000000 to 0.001500)
    0.002915 (0.000000 to 0.008730)
        IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2 (n=56,56)
    0.000000 (0.000000 to 0.001500)
    0.000000 (0.000000 to 0.005000)
        IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2 (n=56,56)
    0.000000 (0.000000 to 0.002000)
    0.000000 (0.000000 to 0.003180)
        IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2 (n=56,56)
    0.000000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.008500)
        IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2 (n=56,56)
    0.000000 (0.000000 to 0.039000)
    0.000000 (0.000000 to 0.001050)
        IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2 (n=56,56)
    0.009500 (0.000000 to 0.055000)
    0.001295 (0.000000 to 0.017150)
        IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2 (n=56,56)
    0.029500 (0.000000 to 0.105000)
    0.003000 (0.000000 to 0.017150)
        IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3 (n=69,69)
    0.002450 (0.000000 to 0.005360)
    0.000000 (0.000000 to 0.001070)
        IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3 (n=69,69)
    0.000696 (0.000000 to 0.006250)
    0.000950 (0.000000 to 0.004030)
        IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3 (n=69,69)
    0.002510 (0.000000 to 0.006480)
    0.000856 (0.000000 to 0.005240)
        IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3 (n=69,69)
    0.000000 (0.000000 to 0.000999)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3 (n=69,69)
    0.000060 (0.000000 to 0.001390)
    0.000000 (0.000000 to 0.000647)
        IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3 (n=69,69)
    0.000122 (0.000000 to 0.002741)
    0.000000 (0.000000 to 0.000905)
        IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3 (n=69,69)
    0.000160 (0.000000 to 0.001990)
    0.000000 (0.000000 to 0.002670)
        IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3 (n=69,69)
    0.000000 (0.000000 to 0.001574)
    0.006290 (0.000930 to 0.022070)
        IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3 (n=69,69)
    0.000090 (0.000000 to 0.001980)
    0.007770 (0.001000 to 0.040020)
        IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3 (n=69,69)
    0.001670 (0.000000 to 0.005550)
    0.000000 (0.000000 to 0.000873)
        IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3 (n=69,69)
    0.001000 (0.000000 to 0.003000)
    0.000000 (0.000000 to 0.000980)
        IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3 (n=69,69)
    0.002000 (0.000000 to 0.007000)
    0.000000 (0.000000 to 0.001060)
        IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3 (n=69,69)
    0.000048 (0.000000 to 0.001480)
    0.000000 (0.000000 to 0.002250)
        IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3 (n=69,69)
    0.000000 (0.000000 to 0.001310)
    0.002340 (0.000000 to 0.006260)
        IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3 (n=69,69)
    0.000180 (0.000000 to 0.001630)
    0.002380 (0.000000 to 0.010000)
        IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3 (n=69,69)
    0.000000 (0.000000 to 0.008000)
    0.000000 (0.000000 to 0.005000)
        IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3 (n=69,69)
    0.000000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.009000)
        IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3 (n=69,69)
    0.002000 (0.000000 to 0.013000)
    0.000000 (0.000000 to 0.007000)
        IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3 (n=69,69)
    0.000000 (0.000000 to 0.013000)
    0.000000 (0.000000 to 0.005000)
        IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3 (n=69,69)
    0.000000 (0.000000 to 0.011000)
    0.003000 (0.000000 to 0.016000)
        IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3 (n=69,69)
    0.020000 (0.000000 to 0.060000)
    0.005000 (0.000000 to 0.017000)
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age

    		 Close Top of page
    End point title
    		 Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age
    End point description
    Percentage of participants with cellular immune response in participants >10 years of age were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was >3 times higher compared to Baseline (Day 1 [M0]) and >=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. PPS with participants >10 years of age included all participants from the FAS who have no major protocol violations and are >10 years of age. Participants analysed are the number of participants with data available for analysis at the given timepoint.
    End point type
    Secondary
    End point timeframe
    Day 14
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    10
    Units: percentage of participants
        number (confidence interval 95%)
    70.0 (34.8 to 93.3)
    No statistical analyses for this end point

    Secondary: Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country

    		 Close Top of page
    End point title
    		 Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country
    End point description
    The phenotype characterization of cellular immune response by country was assessed by ICS by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells). ICS Subset 'by country based on T-cells' included participants from PPS who have IFN-γ ELISPOT responses >500 SFC/million PBMCs and availability of sufficient cells. Number analysed is the number of participants with data available for analysis for specific category.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3
    End point values
    		 TDV 0.5 mL: Panama: CD4+ T Cells TDV 0.5 mL: Philippines: CD4+ T Cells TDV 0.5 mL: Panama: CD8+ T Cells TDV 0.5 ml: Philippines: CD8+ T Cells
    Number of subjects analysed
    33
    46
    33
    46
    Units: percentage of T cells
    median (inter-quartile range (Q1-Q3))
        IFNg+IL2+TNFa+,DENV-2,NS1-2, Day 30(n=28,43,28,43)
    0.005670 (0.001120 to 0.017245)
    0.010590 (0.004880 to 0.020000)
    0.001655 (0.000000 to 0.023500)
    0.001350 (0.000000 to 0.004720)
        IFNg+IL2+TNFa+,DENV-2,NS3-2, Day 30(n=28,43,28,43)
    0.002700 (0.001651 to 0.006900)
    0.006810 (0.002040 to 0.011040)
    0.014500 (0.002155 to 0.036000)
    0.021000 (0.004490 to 0.040260)
        IFNg+IL2+TNFa+,DENV-2,NS5-2, Day 30(n=28,43,28,43)
    0.003892 (0.001960 to 0.007760)
    0.005450 (0.003160 to 0.012000)
    0.021000 (0.002955 to 0.039500)
    0.014000 (0.003084 to 0.049000)
        IFNg+IL2+TNFa-,DENV-2,NS1-2, Day 30(n=28,43,28,43)
    0.000000 (0.000000 to 0.001810)
    0.000000 (0.000000 to 0.000850)
    0.000000 (0.000000 to 0.000545)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2, Day 30(n=28,43,28,43)
    0.000000 (0.000000 to 0.000865)
    0.000000 (0.000000 to 0.000000)
    0.001170 (0.000000 to 0.002990)
    0.001210 (0.000000 to 0.003340)
        IFNg+IL2+TNFa-,DENV-2,NS5-2, Day 30(n=28,43,28,43)
    0.000000 (0.000000 to 0.001013)
    0.000000 (0.000000 to 0.000000)
    0.001825 (0.000000 to 0.004000)
    0.001490 (0.000000 to 0.004640)
        IFNg+IL2-TNFa+,DENV-2,NS1-2, Day 30(n=28,43,28,43)
    0.003935 (0.000208 to 0.006730)
    0.003720 (0.000740 to 0.008820)
    0.024675 (0.000530 to 0.144580)
    0.014000 (0.000190 to 0.030330)
        IFNg+IL2-TNFa+,DENV-2,NS3-2, Day 30(n=28,43,28,43)
    0.002880 (0.000202 to 0.004855)
    0.002710 (0.000130 to 0.006670)
    0.114125 (0.034725 to 0.402570)
    0.172000 (0.065720 to 0.588300)
        IFNg+IL2-TNFa+,DENV-2,NS5-2, Day 30(n=28,43,28,43)
    0.003100 (0.000195 to 0.006109)
    0.002890 (0.000010 to 0.006340)
    0.129260 (0.037645 to 0.344770)
    0.142870 (0.026180 to 0.390000)
        IFNg-IL2+TNFa+,DENV-2,NS1-2, Day 30(n=28,43,28,43)
    0.001820 (0.000000 to 0.004055)
    0.004222 (0.000000 to 0.009470)
    0.000000 (0.000000 to 0.000090)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS3-2, Day 30(n=28,43,28,43)
    0.002110 (0.000000 to 0.009815)
    0.001700 (0.000000 to 0.006610)
    0.000000 (0.000000 to 0.001004)
    0.000000 (0.000000 to 0.000180)
        IFNg-IL2+TNFa+,DENV-2,NS5-2, Day 30(n=28,43,28,43)
    0.003000 (0.000000 to 0.009500)
    0.003350 (0.000000 to 0.008000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa-,DENV-2,NS1-2, Day 30(n=28,43,28,43)
    0.001440 (0.000000 to 0.004830)
    0.000850 (0.000000 to 0.003260)
    0.019265 (0.004200 to 0.078745)
    0.006850 (0.000850 to 0.015340)
        IFNg+IL2-TNFa-,DENV-2,NS3-2, Day 30(n=28,43,28,43)
    0.001240 (0.000000 to 0.002885)
    0.000000 (0.000000 to 0.003160)
    0.065510 (0.025630 to 0.162840)
    0.061520 (0.024540 to 0.287780)
        IFNg+IL2-TNFa-,DENV-2,NS5-2, Day 30(n=28,43,28,43)
    0.000620 (0.000000 to 0.003105)
    0.000498 (0.000000 to 0.003550)
    0.074245 (0.021500 to 0.190910)
    0.053520 (0.014000 to 0.230980)
        IFNg-IL2+TNFa-,DENV-2,NS1-2, Day 30(n=28,43,28,43)
    0.005000 (0.000000 to 0.012145)
    0.000000 (0.000000 to 0.004000)
    0.002000 (0.000000 to 0.010500)
    0.001620 (0.000000 to 0.008000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2, Day 30(n=28,43,28,43)
    0.005000 (0.000000 to 0.011645)
    0.000000 (0.000000 to 0.002000)
    0.000000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.005000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2, Day 30(n=28,43,28,43)
    0.008590 (0.000000 to 0.017500)
    0.000000 (0.000000 to 0.004000)
    0.007000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.008000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2, Day 30(n=28,43,28,43)
    0.000000 (0.000000 to 0.006000)
    0.000000 (0.000000 to 0.030000)
    0.004000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.010000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2, Day 30(n=28,43,28,43)
    0.004500 (0.000000 to 0.025500)
    0.010000 (0.000000 to 0.048000)
    0.008500 (0.003000 to 0.019000)
    0.014000 (0.000000 to 0.040000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2, Day 30(n=28,43,28,43)
    0.000000 (0.000000 to 0.040000)
    0.020000 (0.000000 to 0.050000)
    0.009000 (0.000000 to 0.024500)
    0.002000 (0.000000 to 0.035000)
        IFNg+IL2+TNFa+,DENV-2,NS1-2, Day 90(n=31,41,31,41)
    0.001485 (0.000000 to 0.006030)
    0.005670 (0.002370 to 0.010370)
    0.000000 (0.000000 to 0.002070)
    0.001030 (0.000000 to 0.004850)
        IFNg+IL2+TNFa+,DENV-2,NS3-2, Day 90(n=31,41,31,41)
    0.002448 (0.000000 to 0.007030)
    0.003491 (0.000710 to 0.006290)
    0.003364 (0.000000 to 0.006120)
    0.008860 (0.003110 to 0.016000)
        IFNg+IL2+TNFa+,DENV-2,NS5-2, Day 90(n=31,41,31,41)
    0.001415 (0.000000 to 0.005600)
    0.003270 (0.000791 to 0.005780)
    0.003560 (0.001220 to 0.008740)
    0.005580 (0.000570 to 0.017770)
        IFNg+IL2+TNFa-,DENV-2,NS1-2, Day 90(n=31,41,31,41)
    0.000100 (0.000000 to 0.002130)
    0.000679 (0.000000 to 0.001300)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000722)
        IFNg+IL2+TNFa-,DENV-2,NS3-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.002690)
    0.000515 (0.000000 to 0.001790)
    0.000000 (0.000000 to 0.001320)
    0.000837 (0.000000 to 0.001920)
        IFNg+IL2+TNFa-,DENV-2,NS5-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.001360)
    0.000000 (0.000000 to 0.000921)
    0.000000 (0.000000 to 0.001680)
    0.001175 (0.000000 to 0.003450)
        IFNg+IL2-TNFa+,DENV-2,NS1-2, Day 90(n=31,41,31,41)
    0.000545 (0.000000 to 0.002740)
    0.001290 (0.000000 to 0.002870)
    0.003760 (0.000000 to 0.042000)
    0.005470 (0.000662 to 0.019000)
        IFNg+IL2-TNFa+,DENV-2,NS3-2, Day 90(n=31,41,31,41)
    0.000645 (0.000000 to 0.002690)
    0.002120 (0.000000 to 0.003770)
    0.047980 (0.027290 to 0.154680)
    0.125320 (0.058820 to 0.213810)
        IFNg+IL2-TNFa+,DENV-2,NS5-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.001810)
    0.001120 (0.000000 to 0.003650)
    0.077000 (0.015630 to 0.158700)
    0.067000 (0.021020 to 0.155000)
        IFNg-IL2+TNFa+,DENV-2,NS1-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.001010)
    0.004140 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000950)
        IFNg-IL2+TNFa+,DENV-2,NS3-2, Day 90(n=31,41,31,41)
    0.000793 (0.000000 to 0.003000)
    0.001000 (0.000000 to 0.004230)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000791)
        IFNg-IL2+TNFa+,DENV-2,NS5-2, Day 90(n=31,41,31,41)
    0.001000 (0.000000 to 0.003000)
    0.004530 (0.001220 to 0.008000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000725)
        IFNg+IL2-TNFa-,DENV-2,NS1-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.002120)
    0.000000 (0.000000 to 0.000968)
    0.003210 (0.000000 to 0.019000)
    0.001540 (0.000000 to 0.004780)
        IFNg+IL2-TNFa-,DENV-2,NS3-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.001680)
    0.000000 (0.000000 to 0.000742)
    0.018000 (0.001000 to 0.063760)
    0.037000 (0.011370 to 0.080257)
        IFNg+IL2-TNFa-,DENV-2,NS5-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.002290)
    0.000000 (0.000000 to 0.000949)
    0.020970 (0.003000 to 0.059000)
    0.021940 (0.002890 to 0.036310)
        IFNg-IL2+TNFa-,DENV-2,NS1-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.008000)
    0.000000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.008000)
    0.002000 (0.000000 to 0.011000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2, Day 90(n=31,41,31,41)
    0.004000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.007000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2, Day 90(n=31,41,31,41)
    0.007000 (0.000000 to 0.011000)
    0.002000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.015000)
    0.000000 (0.000000 to 0.010000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.050000)
    0.000000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.009000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.019000)
    0.000000 (0.000000 to 0.036000)
    0.004000 (0.000000 to 0.022000)
    0.020000 (0.002000 to 0.042000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2, Day 90(n=31,41,31,41)
    0.000000 (0.000000 to 0.030000)
    0.026000 (0.000000 to 0.060000)
    0.005000 (0.000000 to 0.017000)
    0.010000 (0.000000 to 0.030000)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Day 120(n=29,46,29,46)
    0.005531 (0.003340 to 0.012780)
    0.009230 (0.003860 to 0.018610)
    0.001590 (0.000000 to 0.006910)
    0.001100 (0.000000 to 0.002580)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Day 120(n=29,46,29,46)
    0.002690 (0.001041 to 0.007190)
    0.003495 (0.001420 to 0.006660)
    0.010000 (0.002850 to 0.016000)
    0.010000 (0.002650 to 0.019000)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Day 120(n=29.46,29,46)
    0.000661 (0.000000 to 0.002990)
    0.002598 (0.000000 to 0.005470)
    0.013000 (0.004830 to 0.021000)
    0.006905 (0.001180 to 0.028000)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Day 120(n=29,46,29,46)
    0.000900 (0.000000 to 0.002580)
    0.001135 (0.000000 to 0.002180)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Day 120(n=29,46,29,46)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001670)
    0.000000 (0.000000 to 0.001440)
    0.000000 (0.000000 to 0.001920)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Day 120(n=29,46,29,46)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001190)
    0.000000 (0.000000 to 0.001650)
    0.001175 (0.000000 to 0.003450)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Day 120(n=29,46,29,46)
    0.002396 (0.000260 to 0.005000)
    0.002045 (0.000000 to 0.005070)
    0.011000 (0.001100 to 0.066340)
    0.005500 (0.000000 to 0.019000)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Day 120(n=29,46,29,46)
    0.002456 (0.000250 to 0.005980)
    0.001800 (0.000000 to 0.003200)
    0.092920 (0.038250 to 0.160000)
    0.153500 (0.048520 to 0.353170)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Day 120(n=29,46,29,46)
    0.001590 (0.000000 to 0.002636)
    0.000702 (0.000000 to 0.002960)
    0.094740 (0.030050 to 0.205000)
    0.096615 (0.031580 to 0.220000)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Day 120(n=29,46,29,46)
    0.005710 (0.000000 to 0.010000)
    0.008335 (0.002900 to 0.017000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Day 120(n=29,46,29,46)
    0.000000 (0.000000 to 0.005520)
    0.000000 (0.000000 to 0.004000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Day 120(n=29,46,29,46)
    0.003580 (0.000000 to 0.008000)
    0.003275 (0.000000 to 0.010660)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001250)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Day 120(n=29,46,29,46)
    0.002490 (0.000000 to 0.005560)
    0.001520 (0.000000 to 0.004380)
    0.006000 (0.001770 to 0.019000)
    0.003750 (0.000000 to 0.007240)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Day 120(n=29,46,29,46)
    0.001620 (0.000000 to 0.002630)
    0.000365 (0.000000 to 0.002000)
    0.033420 (0.009000 to 0.081860)
    0.039000 (0.015000 to 0.104850)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Day 120(n=29,46,29,46)
    0.000000 (0.000000 to 0.002000)
    0.000205 (0.000000 to 0.002830)
    0.022820 (0.012340 to 0.058000)
    0.018425 (0.004130 to 0.060560)
        IFNg-IL2+TNFa-,DENV-2,NS1-2,Day 120(n=29,46,29,46)
    0.010000 (0.000000 to 0.015000)
    0.007000 (0.000000 to 0.012000)
    0.000000 (0.000000 to 0.008000)
    0.002000 (0.000000 to 0.017000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Day 120(n=29,46,29,46)
    0.000000 (0.000000 to 0.005000)
    0.001500 (0.000000 to 0.011000)
    0.005000 (0.000000 to 0.017000)
    0.000000 (0.000000 to 0.012000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Day 120(n=29,46,29,46)
    0.001000 (0.000000 to 0.013000)
    0.000000 (0.000000 to 0.013000)
    0.005000 (0.000000 to 0.015000)
    0.000000 (0.000000 to 0.014000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Day 120(n=29,46,29,46)
    0.001000 (0.000000 to 0.020000)
    0.002000 (0.000000 to 0.030000)
    0.004000 (0.000000 to 0.017000)
    0.003000 (0.000000 to 0.020000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Day 120(n=29,46,29,46)
    0.000000 (0.000000 to 0.030000)
    0.000000 (0.000000 to 0.028000)
    0.010000 (0.000000 to 0.020000)
    0.016500 (0.000000 to 0.033000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Day 120(n=29,46,29,46)
    0.020000 (0.000000 to 0.050000)
    0.015000 (0.000000 to 0.049000)
    0.013000 (0.000000 to 0.027340)
    0.011000 (0.000000 to 0.031000)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Day 270(n=27,44,27,44)
    0.006400 (0.002940 to 0.015180)
    0.005090 (0.002935 to 0.014500)
    0.000000 (0.000000 to 0.003850)
    0.000000 (0.000000 to 0.002285)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Day 270(n=27,44,27,44)
    0.004470 (0.001750 to 0.007780)
    0.001540 (0.000000 to 0.004138)
    0.002920 (0.000020 to 0.014000)
    0.005090 (0.001570 to 0.009779)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Day 270(n=27,44,27,44)
    0.002890 (0.001910 to 0.004530)
    0.002393 (0.000000 to 0.005765)
    0.006040 (0.001120 to 0.030780)
    0.003620 (0.000478 to 0.014160)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.001490)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.002100)
    0.000000 (0.000000 to 0.000915)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.001220)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001220)
    0.000000 (0.000000 to 0.001550)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Day 270(n=27,44,27,44)
    0.000200 (0.000000 to 0.002270)
    0.001386 (0.000000 to 0.003795)
    0.004620 (0.001270 to 0.041450)
    0.004695 (0.000000 to 0.019500)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Day 270(n=27,44,27,44)
    0.002270 (0.000000 to 0.005380)
    0.000740 (0.000000 to 0.002175)
    0.073630 (0.033000 to 0.140000)
    0.099370 (0.034095 to 0.273535)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.001870)
    0.000430 (0.000000 to 0.002875)
    0.093000 (0.022090 to 0.197960)
    0.056525 (0.017440 to 0.183385)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Day 270(n=27,44,27,44)
    0.002000 (0.000000 to 0.012000)
    0.005400 (0.001685 to 0.009780)
    0.000000 (0.000000 to 0.000660)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.005400)
    0.000660 (0.000000 to 0.004630)
    0.000000 (0.000000 to 0.001160)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.004000)
    0.001955 (0.000000 to 0.006600)
    0.000000 (0.000000 to 0.001350)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.002780)
    0.000000 (0.000000 to 0.002015)
    0.004600 (0.000000 to 0.011000)
    0.001669 (0.000000 to 0.007810)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Day 270(n=32,44,27,44)
    0.000000 (0.000000 to 0.002760)
    0.000002 (0.000000 to 0.001615)
    0.015000 (0.004570 to 0.028280)
    0.016169 (0.001670 to 0.047810)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Day 270(n=32,44,27,44)
    0.000000 (0.000000 to 0.003550)
    0.000000 (0.000000 to 0.001285)
    0.018200 (0.006240 to 0.035000)
    0.009090 (0.000030 to 0.025060)
        IFNg-IL2+TNFa-,DENV-2,NS1-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.008000)
    0.001000 (0.000000 to 0.007620)
    0.002000 (0.000000 to 0.009000)
    0.000500 (0.000000 to 0.005680)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.003000)
    0.001000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.001500)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.007000)
    0.000000 (0.000000 to 0.007950)
    0.000000 (0.000000 to 0.008000)
    0.000000 (0.000000 to 0.006000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.020000)
    0.005000 (0.000000 to 0.021000)
    0.000000 (0.000000 to 0.015000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.029000)
    0.005500 (0.000000 to 0.038500)
    0.016000 (0.000000 to 0.040000)
    0.010000 (0.000000 to 0.053000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Day 270(n=27,44,27,44)
    0.000000 (0.000000 to 0.050000)
    0.000000 (0.000000 to 0.040000)
    0.021000 (0.000000 to 0.045000)
    0.010000 (0.000000 to 0.029000)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Year 1(n=32,38,32,38)
    0.002825 (0.000000 to 0.008700)
    0.004303 (0.000000 to 0.007260)
    0.000000 (0.000000 to 0.001720)
    0.000000 (0.000000 to 0.001160)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Year 1(n=32,38,32,38)
    0.001835 (0.000000 to 0.006990)
    0.002138 (0.000000 to 0.004780)
    0.001970 (0.000005 to 0.004610)
    0.000000 (0.000000 to 0.003536)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Year 1(n=32,38,32,38)
    0.001486 (0.000000 to 0.004375)
    0.000538 (0.000000 to 0.006780)
    0.004090 (0.000000 to 0.010820)
    0.000935 (0.000000 to 0.004230)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Year 1(n=32,38,32,38)
    0.000758 (0.000000 to 0.002335)
    0.000000 (0.000000 to 0.001590)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Year 1(n=32,38,32,38)
    0.000035 (0.000000 to 0.001690)
    0.000000 (0.000000 to 0.001140)
    0.000000 (0.000000 to 0.000918)
    0.000000 (0.000000 to 0.001140)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Year 1(n=32,38,32,38)
    0.000000 (0.000000 to 0.001230)
    0.000000 (0.000000 to 0.001620)
    0.000000 (0.000000 to 0.000950)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Year 1(n=32,38,32,38)
    0.000004 (0.000000 to 0.002130)
    0.001599 (0.000010 to 0.005810)
    0.001650 (0.000000 to 0.025930)
    0.000000 (0.000000 to 0.001790)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Year 1(n=32,38,32,38)
    0.001170 (0.000000 to 0.002050)
    0.000965 (0.000000 to 0.003340)
    0.022915 (0.008465 to 0.046500)
    0.022820 (0.004000 to 0.061950)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Year 1(n=32,38,32,38)
    0.001065 (0.000000 to 0.001825)
    0.000766 (0.000000 to 0.003750)
    0.045815 (0.009695 to 0.094410)
    0.009520 (0.000000 to 0.036130)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Year 1(n=32,38,32,38)
    0.002758 (0.000000 to 0.007000)
    0.003735 (0.000000 to 0.011820)
    0.000000 (0.000000 to 0.001010)
    0.000000 (0.000000 to 0.001590)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Year 1(n=32,38,32,38)
    0.000000 (0.000000 to 0.003000)
    0.003000 (0.000000 to 0.008620)
    0.000000 (0.000000 to 0.000035)
    0.000000 (0.000000 to 0.001370)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Year 1(n=32,38,32,38)
    0.001053 (0.000000 to 0.006000)
    0.004910 (0.000060 to 0.014000)
    0.000000 (0.000000 to 0.001315)
    0.000795 (0.000000 to 0.001510)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Year 1(n=32,38,32,38)
    0.000477 (0.000000 to 0.002413)
    0.000788 (0.000000 to 0.002670)
    0.002995 (0.000000 to 0.009535)
    0.000000 (0.000000 to 0.003210)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Year 1(n=32,38,32,38)
    0.000000 (0.000000 to 0.001311)
    0.000000 (0.000000 to 0.002250)
    0.004390 (0.001090 to 0.012525)
    0.002250 (0.000000 to 0.008910)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Year 1(n=32,38,32,38)
    0.000456 (0.000000 to 0.002790)
    0.000000 (0.000000 to 0.001440)
    0.008865 (0.002510 to 0.019285)
    0.000465 (0.000000 to 0.006390)
        IFNg-IL2+TNFa-,DENV-2,NS1-2, Year 1(n=32,38,32,38)
    0.000000 (0.000000 to 0.011000)
    0.002000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.009440)
    0.000500 (0.000000 to 0.009000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Year 1(n=32,38,32,38)
    0.000000 (0.000000 to 0.010000)
    0.001000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.004175)
    0.000000 (0.000000 to 0.008000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Year 1(n=32,38,32,38)
    0.000000 (0.000000 to 0.014500)
    0.005000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 013940)
    0.000500 (0.000000 to 0.009000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Year 1(n=32,38,32,38)
    0.000000 (0.000000 to 0.021000)
    0.020000 (0.000000 to 0.130000)
    0.000000 (0.000000 to 0.003000)
    0.000895 (0.000000 to 0.009000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Year 1(n=32,38,32,38)
    0.000000 (0.000000 to 0.023500)
    0.025500 (0.000000 to 0.100000)
    0.003500 (0.000000 to 0.012500)
    0.010500 (0.000000 to 0.026000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Year 1(n=32,38,32,38)
    0.006500 (0.000000 to 0.085000)
    0.075000 (0.000000 to 0.180000)
    0.005500 (0.000000 to 0.018210)
    0.010000 (0.000000 to 0.022000)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Year 2(n=16,40,16,40)
    0.003832 (0.001292 to 0.007035)
    0.002406 (0.000000 to 0.006890)
    0.000000 (0.000000 to 0.001050)
    0.000000 (0.000000 to 0.000998)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Year 2(n=16,40,16,40)
    0.001452 (0.000337 to 0.005767)
    0.000503 (0.000000 to 0.002644)
    0.002230 (0.000484 to 0.002745)
    0.001875 (0.000000 to 0.004790)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Year 2(n=16,40,16,40)
    0.002005 (0.000323 to 0.007710)
    0.001335 (0.000000 to 0.005545)
    0.002595 (0.001290 to 0.005245)
    0.000812 (0.000000 to 0.005740)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Year 2(n=16,40,16,40)
    0.000261 (0.000000 to 0.001360)
    0.001095 (0.000000 to 0.002335)
    0.002010 (0.000025 to 0.004425)
    0.000000 (0.000000 to 0.004290)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Year 2(n=16,40,16,40)
    0.000413 (0.000000 to 0.001012)
    0.000050 (0.000000 to 0.002470)
    0.012063 (0.003120 to 0.045755)
    0.015970 (0.006810 to 0.069945)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Year 2(n=16,40,16,40)
    0.000656 (0.000000 to 0.001710)
    0.001055 (0.000000 to 0.003220)
    0.018930 (0.008160 to 0.050495)
    0.009770 (0.002160 to 0.054000)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Year 2(N=16,40,16,40)
    0.000895 (0.000000 to 0.003615)
    0.001000 (0.000000 to 0.005000)
    0.000000 (0.000000 to 0.000535)
    0.000000 (0.000000 to 0.000054)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Year 2(N=16,40,16,40)
    0.000000 (0.000000 to 0.002060)
    0.000380 (0.000000 to 0.003775)
    0.000000 (0.000000 to 0.000927)
    0.000000 (0.000000 to 0.000908)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Year 2(N=16,40,16,40)
    0.001555 (0.000000 to 0.008615)
    0.003865 (0.000000 to 0.009705)
    0.000000 (0.000000 to 0.000856)
    0.000000 (0.000000 to 0.000963)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Year 2(n=16,40,16,40)
    0.000702 (0.000000 to 0.002704)
    0.000020 (0.000000 to 0.001690)
    0.000860 (0.000000 to 0.001435)
    0.000030 (0.000000 to 0.002080)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Year 2(n=16,40,16,40)
    0.001005 (0.000000 to 0.001785)
    0.000050 (0.000000 to 0.001196)
    0.004335 (0.002185 to 0.008140)
    0.003555 (0.000850 to 0.007200)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Year 2(n=16,40,16,40)
    0.000985 (0.000000 to 0.001820)
    0.000085 (0.000000 to 0.001405)
    0.005735 (0.002780 to 0.016800)
    0.001155 (0.000000 to 0.007580)
        IFNg-IL2+TNFa-,DENV-2,NS1-2,Year 2(n=16,40,16,40)
    0.000000 (0.000000 to 0.000500)
    0.000000 (0.000000 to 0.003500)
    0.000000 (0.000000 to 0.006325)
    0.000000 (0.000000 to 0.005000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Year 2(n=16,40,16,40)
    0.000000 (0.000000 to 0.003500)
    0.000000 (0.000000 to 0.002000)
    0.002180 (0.000000 to 0.006000)
    0.000000 (0.000000 to 0.001500)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Year 2(n=16,40,16,40)
    0.000500 (0.000000 to 0.022000)
    0.000000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.004385)
    0.000000 (0.000000 to 0.009500)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Year 2(n=16,40,16,40)
    0.000000 (0.000000 to 0.020000)
    0.003500 (0.000000 to 0.044500)
    0.000000 (0.000000 to 0.002870)
    0.000000 (0.000000 to 0.001000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Year 2(n=16,40,16,40)
    0.000000 (0.000000 to 0.030500)
    0.020000 (0.000000 to 0.070000)
    0.004155 (0.000000 to 0.013150)
    0.001295 (0.000000 to 0.019500)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Year 2(n=16,40,16,40)
    0.000500 (0.000000 to 0.065000)
    0.047000 (0.005500 to 0.110000)
    0.001370 (0.000000 to 0.013650)
    0.003500 (0.000000 to 0.020000)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Year 3(n=30,39,30,39)
    0.001810 (0.000000 to 0.007589)
    0.002624 (0.000000 to 0.005010)
    0.000000 (0.000000 to 0.001030)
    0.000000 (0.000000 to 0.001240)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Year 3(n=30,39,30,39)
    0.000530 (0.000000 to 0.003668)
    0.000760 (0.000000 to 0.007520)
    0.000985 (0.000000 to 0.004030)
    0.000844295 (0.000000 to 0.006500)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Year 3(n=30,39,30,39)
    0.001915 (0.000000 to 0.006970)
    0.002884 (0.000000 to 0.006480)
    0.001735 (0.000000 to 0.006330)
    0.000000 (0.000000 to 0.002690)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.000819)
    0.000000 (0.000000 to 0.001137)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.001238)
    0.000080 (0.000000 to 0.001660)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000763)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Year 3(n=30,39,30,39)
    0.001265 (0.000000 to 0.003710)
    0.000000 (0.000000 to 0.001990)
    0.000000 (0.000000 to 0.001150)
    0.000000 (0.000000 to 0.000905)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Year 3(n=30,39,30,39)
    0.000070 (0.000000 to 0.001840)
    0.000540 (0.000000 to 0.002410)
    0.001065 (0.000000 to 0.006760)
    0.000000 (0.000000 to 0.002140)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.001140)
    0.000000 (0.000000 to 0.001800)
    0.007670 (0.002000 to 0.016000)
    0.005610 (0.000600 to 0.025430)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.001120)
    0.001050 (0.000000 to 0.002940)
    0.011465 (0.000000 to 0.045060)
    0.005570 (0.001000 to 0.028163)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Year 3(n=30,39,30,39)
    0.001695 (0.000000 to 0.004320)
    0.001650 (0.000000 to 0.005570)
    0.000000 (0.000000 to 0.001013)
    0.000000 (0.000000 to 0.000873)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Year 3(n=30,39,30,39)
    0.001013 (0.000000 to 0.003000)
    0.001000 (0.000000 to 0.002680)
    0.000000 (0.000000 to 0.001090)
    0.000000 (0.000000 to 0.000813)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Year 3(n=30,39,30,39)
    0.002695 (0.000000 to 0.006000)
    0.001330 (0.000000 to 0.009330)
    0.000000 (0.000000 to 0.001470)
    0.000000 (0.000000 to 0.000617)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.001219)
    0.000300 (0.000000 to 0.001630)
    0.001048 (0.000000 to 0.002680)
    0.000000 (0.000000 to 0.001950)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Year 3(n=30,39,30,39)
    0.000025 (0.000000 to 0.001630)
    0.000000 (0.000000 to 0.001310)
    0.001680 (0.000000 to 0.007000)
    0.002390 (0.000000 to 0.006260)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Year 3(n=30,39,30,39)
    0.000012 (0.000000 to 0.001820)
    0.000584 (0.000000 to 0.001560)
    0.002050 (0.000000 to 0.013360)
    0.002380 (0.000857 to 0.010000)
        IFNg-IL2+TNFa-,DENV-2,NS1-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.006000)
    0.000000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.005000)
    0.000000 (0.000000 to 0.005000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.005000)
    0.001000 (0.000000 to 0.011000)
    0.001000 (0.000000 to 0.019000)
    0.000000 (0.000000 to 0.007000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Year 3(n=30,39,30,39)
    0.021500 (0.000000 to 0.050000)
    0.020000 (0.000000 to 0.090000)
    0.008500 (0.000000 to 0.017000)
    0.001000 (0.000000 to 0.007000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.013000)
    0.000000 (0.000000 to 0.016000)
    0.000500 (0.000000 to 0.011710)
    0.000000 (0.000000 to 0.003000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Year 3(n=30,39,30,39)
    0.000000 (0.000000 to 0.013000)
    0.000000 (0.000000 to 0.010000)
    0.001000 (0.000000 to 0.009000)
    0.008000 (0.000000 to 0.022000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Year 3(n=30,39,30,39)
    0.021500 (0.000000 to 0.050000)
    0.020000 (0.000000 to 0.090000)
    0.008500 (0.000000 to 0.017000)
    0.004000 (0.000000 to 0.015000)
    No statistical analyses for this end point

    Secondary: Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity

    		 Close Top of page
    End point title
    		 Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity
    End point description
    Phenotype characterization of cellular immune response by dengue Baseline seropositivity status assessed by frequency of total CD4+ and CD8+ T cells and was performed in subset of participants with IFN- γ ELISPOT responses >500 SFC/million cells and availability of sufficient cells. Seropositive: reciprocal neutralizing titer (MNT50) >=10 for one or more dengue serotypes. Seronegative: titer value of <10 for all 4 serotypes. Peptide pools included NS for DENV-2 serotype. Data are presented fo different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on type of T cells present in participants at time of analysis (CD4+ and CD8+ T cells). ICS Subset 'by Baseline seropositivity status based on T-cells'. Number analysed:participants with data available for analysis for specific category.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3
    End point values
    		 TDV 0.5 mL: Seropositive: CD4+ T-Cells TDV 0.5 mL: Seronegative: CD4+ T-Cells TDV 0.5 mL: Seropositive: CD8+ T- Cells TDV 0.5 mL: Seronegative: CD8+ T-Cells
    Number of subjects analysed
    44
    35
    44
    35
    Units: percentage of T cells
    median (inter-quartile range (Q1-Q3))
        IFNg+IL2+TNFa+,DENV-2,NS1-2, Day 30(n=39,32,39,32)
    0.013000 (0.004820 to 0.023000)
    0.007655 (0.001679 to 0.011295)
    0.002170 (0.000000 to 0.007600)
    0.000245 (0.000000 to 0.009595)
        IFNg+IL2+TNFa+,DENV-2,NS3-2, Day 30(n=39,32,39,32)
    0.005140 (0.001960 to 0.014000)
    0.004985 (0.001651 to 0.008985)
    0.021000 (0.002540 to 0.039350)
    0.017000 (0.003855 to 0.038500)
        IFNg+IL2+TNFa+,DENV-2,NS5-2, Day 30(n=39,32,39,32)
    0.005380 (0.002410 to 0.012000)
    0.005255 (0.002660 to 0.009030)
    0.018000 (0.002380 to 0.050000)
    0.009560 (0.003965 to 0.028500)
        IFNg+IL2+TNFa-,DENV-2,NS1-2, Day 30(n=39,32,39,32)
    0.000000 (0.000000 to 0.001300)
    0.000000 (0.000000 to 0.001475)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2, Day 30(n=39,32,39,32)
    0.000000 (0.000000 to 0.001060)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.003340)
    0.001330 (0.000000 to 0.002990)
        IFNg+IL2+TNFa-,DENV-2,NS5-2, Day 30(n=39,32,39,32)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001100)
    0.001540 (0.000000 to 0.004160)
    0.001695 (0.000000 to 0.004990)
        IFNg+IL2-TNFa+,DENV-2,NS1-2, Day 30(n=39,32,39,32)
    0.004740 (0.000930 to 0.008483)
    0.003070 (0.000398 to 0.005920)
    0.018190 (0.000000 to 0.066470)
    0.015540 (0.001500 to 0.051595)
        IFNg+IL2-TNFa+,DENV-2,NS3-2, Day 30(n=39,32,39,32)
    0.002710 (0.000000 to 0.006750)
    0.002885 (0.000779 to 0.005040)
    0.108250 (0.052230 to 0.490000)
    0.168175 (0.063270 to 0.431355)
        IFNg+IL2-TNFa+,DENV-2,NS5-2, Day 30(n=39,32,39,32)
    0.002630 (0.001070 to 0.005530)
    0.003785 (0.000000 to 0.007035)
    0.150000 (0.034000 to 0.307000)
    0.117545 (0.027560 to 0.490450)
        IFNg-IL2+TNFa+,DENV-2,NS1-2, Day 30(n=39,32,39,32)
    0.003620 (0.000000 to 0.011000)
    0.002275 (0.000000 to 0.006070)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS3-2, Day 30(n=39,32,39,32)
    0.002150 (0.000000 to 0.008000)
    0.001230 (0.000000 to 0.004635)
    0.000000 (0.000000 to 0.000310)
    0.000000 (0.000000 to 0.001035)
        IFNg-IL2+TNFa+,DENV-2,NS5-2, Day 30(n=39,32,39,32)
    0.003720 (0.000000 to 0.007610)
    0.002270 (0.000000 to 0.009435)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000488)
        IFNg+IL2-TNFa-,DENV-2,NS1-2, Day 30(n=39,32,39,32)
    0.000850 (0.000000 to 0.003640)
    0.000835 (0.000000 to 0.004635)
    0.007750 (0.002150 to 0.035143)
    0.007370 (0.002315 to 0.030290)
        IFNg+IL2-TNFa-,DENV-2,NS3-2, Day 30(n=39,32,39,32)
    0.000000 (0.000000 to 0.003160)
    0.000065 (0.000000 to 0.002450)
    0.065380 (0.013470 to 0.170000)
    0.051500 (0.029850 to 0.238910)
        IFNg+IL2-TNFa-,DENV-2,NS5-2, Day 30(n=39,32,39,32)
    0.000280 (0.000000 to 0.002940)
    0.000900 (0.000000 to 0.004040)
    0.053520 (0.022000 to 0.116020)
    0.101275 (0.017460 to 0.234760)
        IFNg-IL2+TNFa-,DENV-2,NS1-2, Day 30(n=39,32,39,32)
    0.001000 (0.000000 to 0.008000)
    0.000000 (0.000000 to 0.009590)
    0.002000 (0.000000 to 0.008000)
    0.002000 (0.000000 to 0.009500)
        IFNg-IL2+TNFa-,DENV-2,NS3-2, Day 30(n=39,32,39,32)
    0.000000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.003500)
    0.000000 (0.000000 to 0.007730)
    0.000000 (0.000000 to 0.008110)
        IFNg-IL2+TNFa-,DENV-2,NS5-2, Day 30(n=39,32,39,32)
    0.000000 (0.000000 to 0.010000)
    0.00050 (0.000000 to 0.009090)
    0.000000 (0.000000 to 0.010000)
    0.003610 (0.000000 to 0.009500)
        IFNg-IL2-TNFa+,DENV-2,NS1-2, Day 30(n=39,32,39,32)
    0.003000 (0.000000 to 0.030000)
    0.000000 (0.000000 to 0.007000)
    0.005000 (0.000000 to 0.018000)
    0.000000 (0.000000 to 0.004500)
        IFNg-IL2-TNFa+,DENV-2,NS3-2, Day 30(n=39,32,39,32)
    0.010000 (0.000000 to 0.045000)
    0.001500 (0.000000 to 0.030000)
    0.018000 (0.003000 to 0.035000)
    0.006000 (0.000000 to 0.020000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2, Day 30(n=39,32,39,32)
    0.028000 (0.000000 to 0.070000)
    0.000000 (0.000000 to 0.031000)
    0.015000 (0.000000 to 0.032000)
    0.000000 (0.000000 to 0.024500)
        IFNg+IL2+TNFa+,DENV-2,NS1-2, Day 90(n=38,34,38,34)
    0.005720 (0.002968 to 0.010690)
    0.002190 (0.001020 to 0.006030)
    0.000013 (0.000000 to 0.004300)
    0.000000 (0.000000 to 0.002980)
        IFNg+IL2+TNFa+,DENV-2,NS3-2, Day 90(n=38,34,38,34)
    0.003592 (0.000811 to 0.007360)
    0.001325 (0.000000 to 0.005820)
    0.004660 (0.001440 to 0.013770)
    0.005880 (0.001600 to 0.008860)
        IFNg+IL2+TNFa+,DENV-2,NS5-2, Day 90(n=38,34,38,34)
    0.002795 (0.000000 to 0.006900)
    0.001420 (0.000000 to 0.005530)
    0.00326 (0.000000 to 0.014000)
    0.004563 (0.001490 to 0.009010)
        IFNg+IL2+TNFa-,DENV-2,NS1-2, Day 90(n=38,34,38,34)
    0.000842 (0.000000 to 0.001960)
    0.000000 (0.000000 to 0.000888)
    0.000000 (0.000000 to 0.000722)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2, Day 90(n=38,34,38,34)
    0.000544 (0.000000 to 0.002510)
    0.000000 (0.000000 to 0.000824)
    0.000785 (0.000000 to 0.002560)
    0.000000 (0.000000 to 0.001132)
        IFNg+IL2+TNFa-,DENV-2,NS5-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.000921)
    0.000000 (0.000000 to 0.001039)
    0.000383 (0.000000 to 0.001620)
    0.000000 (0.000000 to 0.002050)
        IFNg+IL2-TNFa+,DENV-2,NS1-2, Day 90(n=38,34,38,34)
    0.001540 (0.000000 to 0.003473)
    0.000490 (0.000000 to 0.001370)
    0.002893 (0.000040 to 0.019000)
    0.006540 (0.000000 to 0.024660)
        IFNg+IL2-TNFa+,DENV-2,NS3-2, Day 90(n=38,34,38,34)
    0.001583 (0.000000 to 0.003050)
    0.001810 (0.000000 to 0.003060)
    0.103350 (0.034000 to 0.213810)
    0.107000 (0.031000 to 0.178620)
        IFNg+IL2-TNFa+,DENV-2,NS5-2, Day 90(n=38,34,38,34)
    0.001090 (0.000000 to 0.003265)
    0.000410 (0.000000 to 0.002460)
    0.081000 (0.012110 to 0.129362)
    0.069105 (0.019340 to 0.192000)
        IFNg-IL2+TNFa+,DENV-2,NS1-2, Day 90(n=38,34,38,34)
    0.001245 (0.000000 to 0.007850)
    0.001050 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.000912)
    0.000000 (0.000000 to 0.000650)
        IFNg-IL2+TNFa+,DENV-2,NS3-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.002770)
    0.001880 (0.000000 to 0.004000)
    0.000000 (0.000000 to 0.000791)
    0.000000 (0.000000 to 0.000030)
        IFNg-IL2+TNFa+,DENV-2,NS5-2, Day 90(n=38,34,38,34)
    0.003980 (0.000000 to 0.006330)
    0.002055 (0.000000 to 0.005370)
    0.000000 (0.000000 to 0.000022)
    0.000000 (0.000000 to 0.000725)
        IFNg+IL2-TNFa-,DENV-2,NS1-2, Day 90(n=38,34,38,34)
    0.000010 (0.000000 to 0.001830)
    0.000000 (0.000000 to 0.001080)
    0.002390 (0.000000 to 0.006940)
    0.001535 (0.000000 to 0.005310)
        IFNg+IL2-TNFa-,DENV-2,NS3-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.001070)
    0.000000 (0.000000 to 0.000860)
    0.039000 (0.009950 to 0.096152)
    0.017000 (0.006240 to 0.043000)
        IFNg+IL2-TNFa-,DENV-2,NS5-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.001520)
    0.000000 (0.000000 to 0.000949)
    0.026425 (0.002250 to 0.059000)
    0.015420 (0.004490 to 0.041610)
        IFNg-IL2+TNFa-,DENV-2,NS1-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.009000)
    0.000500 (0.000000 to 0.008000)
    0.002000 (0.000000 to 0.006000)
    0.000500 (0.000000 to 0.012000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.009000)
    0.002000 (0.000000 to 0.010000)
    0.000500 (0.000000 to 0.008000)
    0.000000 (0.000000 to 0.011000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2, Day 90(n=38,34,38,34)
    0.001500 (0.000000 to 0.010000)
    0.006500 (0.000000 to 0.013000)
    0.000000 (0.000000 to 0.009000)
    0.001000 (0.000000 to 0.011000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.008000)
    0.000000 (0.000000 to 0.012000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.036000)
    0.001000 (0.000000 to 0.020000)
    0.008405 (0.001000 to 0.038000)
    0.018000 (0.000000 to 0.032000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2, Day 90(n=38,34,38,34)
    0.000000 (0.000000 to 0.050000)
    0.010405 (0.000000 to 0.050000)
    0.005450 (0.000000 to 0.027000)
    0.009500 (0.000000 to 0.026000)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Day 120(n=42,33,42,33)
    0.011000 (0.003860 to 0.017000)
    0.005531 (0.003340 to 0.016010)
    0.00140 (0.000000 to 0.004030)
    0.001320 (0.000000 to 0.004240)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Day 120(n=42,33,42,33)
    0.003480 (0.000000 to 0.008830)
    0.003300 (0.001670 to 0.005510)
    0.010000 (0.002650 to 0.028000)
    0.010000 (0.002740 to 0.015000)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Day 120(n=42,33,42,33)
    0.002705 (0.000000 to 0.005470)
    0.001460 (0.000000 to 0.003000)
    0.012000 (0.002670 to 0.035000)
    0.006000 (0.002230 to 0.013000)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Day 120(n=42,33,42,33)
    0.000975 (0.000000 to 0.002670)
    0.001220 (0.000000 to 0.001840)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Day 120(n=42,33,42,33)
    0.000000 (0.000000 to 0.001580)
    0.000000 (0.000000 to 0.001150)
    0.000000 (0.000000 to 0.001920)
    0.000000 (0.000000 to 0.001460)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Day 120(n=42,33,42,33)
    0.000000 (0.000000 to 0.000908)
    0.000000 (0.000000 to 0.000953)
    0.001540 (0.000000 to 0.003450)
    0.000000 (0.000000 to 0.001650)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Day 120(n=42,33,42,33)
    0.002885 (0.000760 to 0.005320)
    0.002070 (0.000000 to 0.003680)
    0.007155 (0.000000 to 0.036000)
    0.007850 (0.000000 to 0.028000)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Day 120(n=42,33,42,33)
    0.002915 (0.001090 to 0.004370)
    0.000450 (0.000000 to 0.002670)
    0.144565 (0.039110 to 0.447000)
    0.093000 (0.053410 to 0.163270)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Day 120(n=42,33,42,33)
    0.000702 (0.000000 to 0.003690)
    0.001570 (0.000000 to 0.002150)
    0.102525 (0.039880 to 0.291210)
    0.078900 (0.025190 to 0.134400)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Day 120(n=42,33,42,33)
    0.004735 (0.000280 to 0.013000)
    0.011430 (0.003910 to 0.017000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Day 120(n=42,33,42,33)
    0.000530 (0.000000 to 0.005520)
    0.000000 (0.000000 to 0.003730)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001140)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Day 120(n=42,33,42,33)
    0.003100 (0.000000 to 0.007000)
    0.006490 (0.000000 to 0.010660)
    0.000000 (0.000000 to 0.001420)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Day 120(n=42,33,42,33)
    0.001520 (0.000000 to 0.004710)
    0.002490 (0.000000 to 0.005030)
    0.004280 (0.001060 to 0.009270)
    0.004080 (0.000000 to 0.016790)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Day 120(n=42,33,42,33)
    0.001235 (0.000000 to 0.002480)
    0.000190 (0.000000 to 0.002720)
    0.046825 (0.015000 to 0.111210)
    0.024000 (0.007000 to 0.056110)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Day 120(n=42,33,42,33)
    0.000020 (0.000000 to 0.002480)
    0.000000 (0.000000 to 0.002260)
    0.034610 (0.011000 to 0.101210)
    0.016280 (0.006480 to 0.030630)
        IFNg-IL2+TNFa-,DENV-2,NS1-2,Day 120(n=42,33,42,33)
    0.009500 (0.000000 to 0.011000)
    0.006000 (0.000000 to 0.015000)
    0.001500 (0.000000 to 0.017000)
    0.002000 (0.000000 to 0.014000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Day 120(n=42,33,42,33)
    0.000000 (0.000000 to 0.007000)
    0.002000 (0.000000 to 0.011000)
    0.000500 (0.000000 to 0.019000)
    0.003000 (0.000000 to 0.012000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Day 120(n=42,33,42,33)
    0.000000 (0.000000 to 0.013000)
    0.000000 (0.000000 to 0.013000)
    0.000000 (0.000000 to 0.011000)
    0.006000 (0.000000 to 0.020000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Day 120(n=42,33,42,33)
    0.007000 (0.000000 to 0.040000)
    0.000000 (0.000000 to 0.019000)
    0.004500 (0.000000 to 0.028000)
    0.000000 (0.000000 to 0.014000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Day 120(n=42,33,42,33)
    0.008000 (0.000000 to 0.030000)
    0.000000 (0.000000 to 0.028000)
    0.018000 (0.000000 to 0.034000)
    0.009000 (0.000000 to 0.019000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Day 120(n=42,33,42,33)
    0.020000 (0.000000 to 0.050000)
    0.010000 (0.000000 to 0.040000)
    0.016500 (0.000000 to 0.040000)
    0.008000 (0.000000 to 0.023050)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Day 270(n=39,32,39,32)
    0.008790 (0.002970 to 0.019000)
    0.004355 (0.002620 to 0.011890)
    0.000000 (0.000000 to 0.002760)
    0.000411 (0.000000 to 0.002420)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Day 270(n=39,32,39,32)
    0.003410 (0.000000 to 0.006810)
    0.002170 (0.000355 to 0.004995)
    0.008760 (0.002360 to 0.020000)
    0.002605 (0.000010 to 0.008395)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Day 270(n=39,32,39,32)
    0.002890 (0.001110 to 0.005160)
    0.002720 (0.000059 to 0.005480)
    0.003960 (0.001120 to 0.026000)
    0.004575 (0.000000 to 0.012420)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.000980)
    0.000000 (0.000000 to 0.000505)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001930)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000635)
    0.000000 (0.000000 to 0.001570)
    0.000000 (0.000000 to 0.001150)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Day 270(n=39,32,39,32)
    0.001650 (0.000000 to 0.004170)
    0.000190 (0.000000 to 0.002215)
    0.003430 (0.000000 to 0.019000)
    0.008115 (0.000030 to 0.024475)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Day 270(n=39,32,39,32)
    0.001470 (0.000000 to 0.003600)
    0.000803 (0.000000 to 0.003250)
    0.099000 (0.036000 to 0.289000)
    0.069910 (0.027000 to 0.176500)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.002240)
    0.000798 (0.000000 to 0.002785)
    0.070000 (0.029000 to 0.258000)
    0.055015 (0.016265 to 0.128520)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Day 270(n=39,32,39,32)
    0.003230 (0.000000 to 0.009190)
    0.005735 (0.001130 to 0.013520)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.004920)
    0.000515 (0.000000 to 0.004630)
    0.000000 (0.000000 to 0.000055)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Day 270(n=39,32,39,32)
    0.001000 (0.000000 to 0.003470)
    0.002470 (0.000000 to 0.007075)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.001470)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.002800)
    0.000000 (0.000000 to 0.001245)
    0.003060 (0.000000 to 0.008450)
    0.003350 (0.000000 to 0.008815)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Day 270(n=39,32,39,32)
    0.000330 (0.000000 to 0.002550)
    0.000000 (0.000000 to 0.001390)
    0.022120 (0.002960 to 0.032080)
    0.007160 (0.002385 to 0.016904)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.003160)
    0.000000 (0.000000 to 0.002085)
    0.015270 (0.000620 to 0.033830)
    0.008945 (0.002924 to 0.027280)
        IFNg-IL2+TNFa-,DENV-2,NS1-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.006000)
    0.001500 (0.000000 to 0.010500)
    0.000000 (0.000000 to 0.006000)
    0.001000 (0.000000 to 0.008500)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.004000)
    0.000000 (0.000000 to 0.001000)
    0.000000 (0.000000 to 0.005000)
    0.000000 (0.000000 to 0.003500)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.007000)
    0.000000 (0.000000 to 0.007500)
    0.000000 (0.000000 to 0.007460)
    0.000000 (0.000000 to 0.005500)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Day 270(n=39,32,39,32)
    0.000000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.005000)
    0.003000 (0.000000 to 0.029000)
    0.000000 (0.000000 to 0.015000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Day 270(n=27,44,27,44)
    0.019000 (0.000000 to 0.050000)
    0.000000 (0.000000 to 0.011500)
    0.026000 (0.006000 to 0.070000)
    0.004000 (0.000000 to 0.028500)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Day 270(n=39,32,39,32)
    0.009000 (0.000000 to 0.050000)
    0.000000 (0.000000 to 0.027000)
    0.015000 (0.004000 to 0.047000)
    0.006000 (0.000000 to 0.024500)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Year 1(n=39,31,39,31)
    0.006710 (0.001620 to 0.010000)
    0.000000 (0.000000 to 0.004370)
    0.000000 (0.000000 to 0.002310)
    0.000000 (0.000000 to 0.000870)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Year 1(n=39,31,39,31)
    0.002960 (0.000000 to 0.006980)
    0.001590 (0.000000 to 0.004050)
    0.000170 (0.000000 to 0.005020)
    0.002000 (0.000000 to 0.003420)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Year 1(n=39,31,39,31)
    0.003220 (0.000000 to 0.007550)
    0.000000 (0.000000 to 0.002285)
    0.002460 (0.000000 to 0.010000)
    0.001200 (0.000000 to 0.004260)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Year 1(n=39,31,39,31)
    0.000745 (0.000000 to 0.001700)
    0.000000 (0.000000 to 0.002180)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Year 1(n=39,31,39,31)
    0.000000 (0.000000 to 0.001240)
    0.000000 (0.000000 to 0.001510)
    0.000000 (0.000000 to 0.001330)
    0.000000 (0.000000 to 0.000060)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Year 1(n=39,31,39,31)
    0.000000 (0.000000 to 0.001620)
    0.000000 (0.000000 to 0.000789)
    0.000000 (0.000000 to 0.000961)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Year 1(n=39,31,39,31)
    0.001110 (0.000000 to 0.004180)
    0.000920 (0.000000 to 0.002310)
    0.000000 (0.000000 to 0.015000)
    0.000000 (0.000000 to 0.007750)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Year 1(n=39,31,39,31)
    0.001430 (0.000240 to 0.002718)
    0.000170 (0.000000 to 0.002810)
    0.033910 (0.007790 to 0.061950)
    0.013000 (0.004000 to 0.038490)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Year 1(n=39,31,39,31)
    0.001058 (0.000000 to 0.003260)
    0.000522 (0.000000 to 0.002760)
    0.036130 (0.006450 to 0.126150)
    0.010120 (0.001030 to 0.040000)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Year 1(n=39,31,39,31)
    0.003000 (0.000000 to 0.011820)
    0.003000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.001260)
    0.000000 (0.000000 to 0.001020)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Year 1(n=39,31,39,31)
    0.003000 (0.000000 to 0.006820)
    0.001000 (0.000000 to 0.005000)
    0.000000 (0.000000 to 0.000794)
    0.000000 (0.000000 to 0.001130)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Year 1(n=39,31,39,31)
    0.002000 (0.000000 to 0.011000)
    0.004000 (0.000000 to 0.012000)
    0.000000 (0.000000 to 0.001680)
    0.000000 (0.000000 to 0.001330)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Year 1(n=39,31,39,31)
    0.000190 (0.000000 to 0.002580)
    0.000746 (0.000000 to 0.002670)
    0.000000 (0.000000 to 0.006880)
    0.001300 (0.000000 to 0.005200)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Year 1(n=39,31,39,31)
    0.000000 (0.000000 to 0.001802)
    0.000000 (0.000000 to 0.002430)
    0.003000 (0.000000 to 0.012095)
    0.003150 (0.000000 to 0.009260)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Year 1(n=39,31,39,31)
    0.000070 (0.000000 to 0.001880)
    0.000000 (0.000000 to 0.001900)
    0.003000 (0.000000 to 0.025100)
    0.003800 (0.000000 to 0.012000)
        IFNg-IL2+TNFa-,DENV-2,NS1-2, Year 1(n=39,31,39,31)
    0.000000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.010000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Year 1(n=39,31,39,31)
    0.000000 (0.000000 to 0.010000)
    0.002000 (0.000000 to 0.015000)
    0.000000 (0.000000 to 0.007000)
    0.000000 (0.000000 to 0.009000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Year 1(n=39,31,39,31)
    0.000000 (0.000000 to 0.018000)
    0.006000 (0.000000 to 0.020000)
    0.001000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.010000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Year 1(n=39,31,39,31)
    0.000000 (0.000000 to 0.060000)
    0.020000 (0.000000 to 0.060000)
    0.000000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.003000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Year 1(n=39,31,39,31)
    0.000000 (0.000000 to 0.090000)
    0.010000 (0.000000 to 0.060000)
    0.006000 (0.000000 to 0.024000)
    0.004420 (0.000000 to 0.017000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Year 1(n=39,31,39,31)
    0.057000 (0.000000 to 0.100000)
    0.034000 (0.000000 to 0.140000)
    0.007000 (0.000000 to 0.031000)
    0.007000 (0.000000 to 0.017420)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Year 2(n=31,25,31,25)
    0.003744 (0.001870 to 0.009000)
    0.001200 (0.000000 to 0.003920)
    0.000000 (0.000000 to 0.001040)
    0.000000 (0.000000 to 0.001100)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Year 2(n=31,25,31,25)
    0.000613 (0.000000 to 0.004954)
    0.000860 (0.000000 to 0.002303)
    0.002100 (0.000786 to 0.004890)
    0.000042 (0.000000 to 0.002950)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Year 2(n=31,25,31,25)
    0.001490 (0.000000 to 0.003990)
    0.001510 (0.000050 to 0.005870)
    0.001700 (0.000000 to 0.005170)
    0.001340 (0.000000 to 0.005320)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Year 2(n=31,25,31,25)
    0.000000 (0.000000 to 0.001820)
    0.000000 (0.000000 to 0.000948)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Year 2(n=31,25,31,25)
    0.000000 (0.000000 to 0.000751)
    0.000000 (0.000000 to 0.000954)
    0.000000 (0.000000 to 0.000030)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Year 2(n=31,25,31,25)
    0.000000 (0.000000 to 0.002170)
    0.000000 (0.000000 to 0.000803)
    0.000000 (0.000000 to 0.000953)
    0.000000 (0.000000 to 0.001190)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Year 2(n=31,25,31,25)
    0.001190 (0.000045 to 0.001810)
    0.000120 (0.000000 to 0.002640)
    0.001720 (0.000000 to 0.006280)
    0.000000 (0.000000 to 0.002570)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Year 2(n=31,25,31,25)
    0.000000 (0.000000 to 0.001950)
    0.000150 (0.000000 to 0.000948)
    0.025000 (0.008990 to 0.067240)
    0.007800 (0.002640 to 0.046410)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Year 2(n=31,25,31,25)
    0.000631 (0.000000 to 0.002210)
    0.001390 (0.000000 to 0.002410)
    0.015650 (0.002880 to 0.054000)
    0.012220 (0.003480 to 0.028820)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Year 2(N=31,25,31,25)
    0.001000 (0.000000 to 0.005000)
    0.000380 (0.000000 to 0.003510)
    0.000000 (0.000000 to 0.000835)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Year 2(N=31,25,31,25)
    0.000760 (0.000000 to 0.006670)
    0.000000 (0.000000 to 0.003070)
    0.000000 (0.000000 to 0.000852)
    0.000000 (0.000000 to 0.001130)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Year 2(N=31,25,31,25)
    0.002000 (0.000000 to 0.008760)
    0.005000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.000940)
    0.000000 (0.000000 to 0.000947)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Year 2(n=31,25,31,25)
    0.000320 (0.000000 to 0.002130)
    0.000588 (0.000000 to 0.002100)
    0.000670 (0.000000 to 0.001940)
    0.000000 (0.000000 to 0.002020)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Year 2(n=31,25,31,25)
    0.000180 (0.000000 to 0.001130)
    0.000578 (0.000000 to 0.001680)
    0.004920 (0.002000 to 0.007370)
    0.003380 (0.000130 to 0.007030)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Year 2(n=31,25,31,25)
    0.000621 (0.000000 to 0.001449)
    0.000017 (0.000000 to 0.001550)
    0.004580 (0.000000 to 0.009150)
    0.001140 (0.000000 to 0.007210)
        IFNg-IL2+TNFa-,DENV-2,NS1-2,Year 2(n=31,25,31,25)
    0.000000 (0.000000 to 0.004000)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.005000)
    0.000000 (0.000000 to 0.007000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Year 2(n=31,25,31,25)
    0.000000 (0.000000 to 0.002000)
    0.000000 (0.000000 to 0.002000)
    0.000000 (0.000000 to 0.003000)
    0.000000 (0.000000 to 0.006000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Year 2(n=31,25,31,25)
    0.000000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.016000)
    0.000000 (0.000000 to 0.005360)
    0.000000 (0.000000 to 0.009000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Year 2(n=31,25,31,25)
    0.000000 (0.000000 to 0.049000)
    0.000000 (0.000000 to 0.022000)
    0.000000 (0.000000 to 0.004640)
    0.000000 (0.000000 to 0.000000)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Year 2(n=31,25,31,25)
    0.011000 (0.000000 to 0.050000)
    0.006000 (0.000000 to 0.060000)
    0.008310 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.014000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Year 2(n=31,25,31,25)
    0.044000 (0.001000 to 0.100000)
    0.018000 (0.000000 to 0.110000)
    0.004000 (0.000000 to 0.020000)
    0.000000 (0.000000 to 0.014300)
        IFNg+IL2+TNFa+,DENV-2,NS1-2,Year 3(n=38,31,38,31)
    0.003110 (0.000000 to 0.008297)
    0.001934 (0.000180 to 0.004290)
    0.000000 (0.000000 to 0.001070)
    0.000000 (0.000000 to 0.001460)
        IFNg+IL2+TNFa+,DENV-2,NS3-2,Year 3(n=38,31,38,31)
    0.000645 (0.000000 to 0.007000)
    0.000760 (0.000000 to 0.006250)
    0.000060 (0.000000 to 0.003050)
    0.001830 (0.000000 to 0.004090)
        IFNg+IL2+TNFa+,DENV-2,NS5-2,Year 3(n=38,31,38,31)
    0.002612 (0.000000 to 0.007300)
    0.002510 (0.000000 to 0.003800)
    0.001420 (0.000000 to 0.006330)
    0.000000 (0.000000 to 0.002690)
        IFNg+IL2+TNFa-,DENV-2,NS1-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.000831)
    0.000000 (0.000000 to 0.001180)
    0.000000 (0.000000 to 0.000000)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS3-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.001240)
    0.000778 (0.000000 to 0.001670)
    0.000000 (0.000000 to 0.000811)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2+TNFa-,DENV-2,NS5-2,Year 3(n=38,31,38,31)
    0.000686 (0.000000 to 0.002770)
    0.000000 (0.000000 to 0.002070)
    0.000000 (0.000000 to 0.001290)
    0.000000 (0.000000 to 0.000000)
        IFNg+IL2-TNFa+,DENV-2,NS1-2,Year 3(n=38,31,38,31)
    0.000070 (0.000000 to 0.002070)
    0.000557 (0.000000 to 0.001940)
    0.000000 (0.000000 to 0.003040)
    0.000000 (0.000000 to 0.002560)
        IFNg+IL2-TNFa+,DENV-2,NS3-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.001660)
    0.000000 (0.000000 to 0.001574)
    0.012470 (0.002000 to 0.023163)
    0.004220 (0.000210 to 0.014900)
        IFNg+IL2-TNFa+,DENV-2,NS5-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.001580)
    0.001050 (0.000000 to 0.002364)
    0.007735 (0.001000 to 0.053360)
    0.007770 (0.000832 to 0.029000)
        IFNg-IL2+TNFa+,DENV-2,NS1-2,Year 3(n=38,31,38,31)
    0.001740 (0.000000 to 0.005570)
    0.001650 (0.000000 to 0.004000)
    0.000000 (0.000000 to 0.000873)
    0.000000 (0.000000 to 0.000930)
        IFNg-IL2+TNFa+,DENV-2,NS3-2,Year 3(n=38,31,38,31)
    0.000880 (0.000000 to 0.002680)
    0.001000 (0.000000 to 0.003810)
    0.000000 (0.000000 to 0.000750)
    0.000000 (0.000000 to 0.001890)
        IFNg-IL2+TNFa+,DENV-2,NS5-2,Year 3(n=38,31,38,31)
    0.001500 (0.000000 to 0.008170)
    0.002170 (0.000000 to 0.006000)
    0.000000 (0.000000 to 0.001230)
    0.000000 (0.000000 to 0.000150)
        IFNg+IL2-TNFa-,DENV-2,NS1-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.000702)
    0.000864 (0.000000 to 0.002005)
    0.000000 (0.000000 to 0.001820)
    0.000090 (0.000000 to 0.002680)
        IFNg+IL2-TNFa-,DENV-2,NS3-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.001637)
    0.000000 (0.000000 to 0.001310)
    0.002707 (0.000000 to 0.006560)
    0.002320 (0.000000 to 0.006260)
        IFNg+IL2-TNFa-,DENV-2,NS5-2,Year 3(n=38,31,38,31)
    0.000523 (0.000000 to 0.001820)
    0.000000 (0.000000 to 0.001560)
    0.002955 (0.000000 to 0.011250)
    0.001070 (0.000000 to 0.006670)
        IFNg-IL2+TNFa-,DENV-2,NS1-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.006000)
    0.000000 (0.000000 to 0.009000)
    0.000040 (0.000000 to 0.005000)
    0.000000 (0.000000 to 0.003000)
        IFNg-IL2+TNFa-,DENV-2,NS3-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.010000)
    0.003000 (0.000000 to 0.009000)
    0.000000 (0.000000 to 0.004830)
    0.000000 (0.000000 to 0.010000)
        IFNg-IL2+TNFa-,DENV-2,NS5-2,Year 3(n=38,31,38,31)
    0.000500 (0.000000 to 0.015000)
    0.004000 (0.000000 to 0.013000)
    0.000500 (0.000000 to 0.007000)
    0.000000 (0.000000 to 0.006000)
        IFNg-IL2-TNFa+,DENV-2,NS1-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.030000)
    0.000000 (0.000000 to 0.010000)
    0.000000 (0.000000 to 0.004000)
    0.000000 (0.000000 to 0.011710)
        IFNg-IL2-TNFa+,DENV-2,NS3-2,Year 3(n=38,31,38,31)
    0.000000 (0.000000 to 0.011000)
    0.000000 (0.000000 to 0.012000)
    0.004000 (0.000000 to 0.014000)
    0.001270 (0.000000 to 0.026000)
        IFNg-IL2-TNFa+,DENV-2,NS5-2,Year 3(n=38,31,38,31)
    0.023000 (0.000000 to 0.060000)
    0.016000 (0.000000 to 0.070000)
    0.003000 (0.000000 to 0.016000)
    0.008000 (0.000000 to 0.018000)
    No statistical analyses for this end point

    Secondary: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years

    		 Close Top of page
    End point title
    		 Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years
    End point description
    GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. PPS included all participants from the FAS who have no major protocol violations. Number analysed is the number of participants with data available for analysis at the given timepoint.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    195
    Units: titer
    geometric mean (confidence interval 95%)
        DENV-1, Day 30
    402.3 (287.5 to 562.9)
        DENV-2, Day 30
    5482.2 (4626.4 to 6496.3)
        DENV-3, Day 30
    436.1 (326.9 to 581.7)
        DENV-4, Day 30
    253.9 (182.6 to 353.1)
        DENV-1, Day 90
    271.7 (193.9 to 380.7)
        DENV-2, Day 90
    2736.3 (2295.1 to 3262.5)
        DENV-3, Day 90
    218.7 (162.0 to 295.2)
        DENV-4, Day 90
    177.4 (129.6 to 242.8)
        DENV-1, Day 120
    550.6 (408.0 to 743.1)
        DENV-2, Day 120
    2808.2 (2395.0 to 3292.8)
        DENV-3, Day 120
    404.2 (312.6 to 522.7)
        DENV-4, Day 120
    427.1 (335.4 to 543.8)
        DENV-1, Day 270
    343.3 (249.8 to 471.6)
        DENV-2, Day 270
    1729.9 (1435.7 to 2084.4)
        DENV-3, Day 270
    203.8 (153.5 to 270.7)
        DENV-4, Day 270
    186.6 (141.6 to 246.0)
        DENV-1, Year 1
    243.8 (176.4 to 337.0)
        DENV-2, Year 1
    896.2 (729.9 to 1100.5)
        DENV-3, Year 1
    148.6 (111.6 to 197.7)
        DENV-4, Year 1
    142.4 (108.8 to 186.3)
        DENV-1, Year 2
    290.8 (200.8 to 421.1)
        DENV-2, Year 2
    724.7 (564.2 to 930.8)
        DENV-3, Year 2
    172.7 (120.6 to 247.1)
        DENV-4, Year 2
    157.7 (114.0 to 218.0)
        DENV-1, Year 3
    178.7 (127.3 to 250.8)
        DENV-2, Year 3
    546.4 (435.2 to 686.0)
        DENV-3, Year 3
    125.2 (92.8 to 169.0)
        DENV-4, Year 3
    91.6 (69.4 to 120.7)
    No statistical analyses for this end point

    Secondary: Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years

    		 Close Top of page
    End point title
    		 Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years
    End point description
    Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. PPS included all participants from the FAS who have no major protocol violations. Number analysed is the number of participants with data available at the given timepoint.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    195
    Units: percentage of participants
    number (confidence interval 95%)
        DENV-1, Day 30
    96.8 (93.1 to 98.8)
        DENV-2, Day 30
    99.5 (97.0 to 100.0)
        DENV-3, Day 30
    99.5 (97.0 to 100.0)
        DENV-4, Day 30
    93.0 (88.3 to 96.2)
        DENV-1, Day 90
    90.8 (85.8 to 94.4)
        DENV-2, Day 90
    99.5 (97.2 to 100.0)
        DENV-3, Day 90
    94.4 (90.1 to 97.2)
        DENV-4, Day 90
    91.8 (87.0 to 95.2)
        DENV-1, Day 120
    99.5 (97.0 to 100.0)
        DENV-2, Day 120
    100.0 (98.0 to 100.0)
        DENV-3, Day 120
    100.0 (98.0 to 100.0)
        DENV-4, Day 120
    100.0 (98.0 to 100.0)
        DENV-1, Day 270
    96.8 (93.1 to 98.8)
        DENV-2, Day 270
    100.0 (98.0 to 100.0)
        DENV-3, Day 270
    97.9 (94.6 to 99.4)
        DENV-4, Day 270
    96.8 (93.1 to 98.8)
        DENV-1, Year 1
    91.1 (86.2 to 94.8)
        DENV-2, Year 1
    100.0 (98.1 to 100.0)
        DENV-3, Year 1
    93.8 (89.3 to 96.7)
        DENV-4, Year 1
    96.4 (92.6 to 98.5)
        DENV-1, Year 2
    93.5 (88.4 to 96.8)
        DENV-2, Year 2
    100.0 (97.6 to 100.0)
        DENV-3, Year 2
    89.6 (83.7 to 93.9)
        DENV-4, Year 2
    95.5 (90.9 to 98.2)
        DENV-1, Year 3
    84.4 (78.3 to 89.4)
        DENV-2, Year 3
    100.0 (98.0 to 100.0)
        DENV-3, Year 3
    86.7 (80.8 to 91.3)
        DENV-4, Year 3
    86.1 (80.2 to 90.8)
    No statistical analyses for this end point

    Secondary: Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years

    		 Close Top of page
    End point title
    		 Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years
    End point description
    Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent. Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent.PPS included all participants from the FAS who have no major protocol violations. Number analysed is the number of participants with data available for analysis at the given timepoint.
    End point type
    Secondary
    End point timeframe
    1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    195
    Units: percentage of participants
    number (confidence interval 95%)
        Tetravalent, Day 30
    90.8 (85.7 to 94.6)
        At Least Trivalent, Day 30
    98.4 (95.3 to 99.7)
        Tetravalent, Day 90
    83.6 (77.6 to 88.5)
        At Least Trivalent, Day 90
    95.4 (91.4 to 97.9)
        Tetravalent, Day 120
    99.5 (97.0 to 100.0)
        At Least Trivalent, Day 120
    100.0 (98.0 to 100.0)
        Tetravalent, Day 270
    93.0 (88.4 to 96.2)
        At Least Trivalent, Day 270
    98.4 (95.4 to 99.7)
        Tetravalent, Year 1
    87.5 (82.0 to 91.8)
        At Least Trivalent, Year 1
    95.3 (91.3 to 97.8)
        Tetravalent, Year 2
    86.4 (79.9 to 91.4)
        At Least Trivalent, Year 2
    93.5 (88.4 to 96.8)
        Tetravalent, Year 3
    76.7 (69.8 to 82.6)
        At Least Trivalent, Year 3
    87.2 (81.4 to 91.7)
    No statistical analyses for this end point

    Secondary: Percentage of Participants Experiencing Unsolicited Adverse Events (AE)

    		 Close Top of page
    End point title
    		 Percentage of Participants Experiencing Unsolicited Adverse Events (AE)
    End point description
    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Safety Set included all enrolled participants who received at least 1 dose of TDV. Number analysed is the number of participants with data available for analysis at the given timepoint.
    End point type
    Secondary
    End point timeframe
    Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    200
    Units: percentage of participants
    number (not applicable)
        After First Vaccination
    26.5
        After Second Vaccination
    25.3
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Serious Adverse Events (SAEs)

    		 Close Top of page
    End point title
    		 Percentage of Participants With Serious Adverse Events (SAEs)
    End point description
    A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Safety Set included all enrolled participants who received at least 1 dose of TDV.
    End point type
    Secondary
    End point timeframe
    From first vaccination (Day 1) up to end of study (Approximately 3 years)
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    200
    Units: percentage of participants
        number (not applicable)
    5.5
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Medically Attended AEs (MAAEs)

    		 Close Top of page
    End point title
    		 Percentage of Participants With Medically Attended AEs (MAAEs)
    End point description
    MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria. Safety Set included all enrolled participants who received at least 1 dose of TDV.
    End point type
    Secondary
    End point timeframe
    From first vaccination (Day 1) up to 6 months post second vaccination (Day 270)
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    200
    Units: percentage of participants
        number (not applicable)
    50.5
    No statistical analyses for this end point

    Secondary: Percentage of Participants With Virologically Confirmed Dengue

    		 Close Top of page
    End point title
    		 Percentage of Participants With Virologically Confirmed Dengue
    End point description
    Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR). Safety Set included all enrolled participants who received at least 1 dose of TDV.
    End point type
    Secondary
    End point timeframe
    From first vaccination (Day 1) up to 6 months post second vaccination (Day 270)
    End point values
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Number of subjects analysed
    200
    Units: percentage of participants
        number (not applicable)
    6.0
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All-cause mortality and SAEs: From first vaccination(Day 1) up to end of study (Approximately 3 years);Non-SAEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1[Month 0] and Day 90[Month 3]
    Adverse event reporting additional description
    At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    21.0
    Reporting groups
    Reporting group title
    Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Reporting group description
    		 TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).

    Serious adverse events
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Total subjects affected by serious adverse events
         subjects affected / exposed
    11 / 200 (5.50%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Injury, poisoning and procedural complications
    Foot fracture
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Febrile convulsion
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Social circumstances
    Victim of sexual abuse
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Faecaloma
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastritis
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Biliary colic
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Asthma
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Urosepsis
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Typhoid fever
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Dengue fever
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastroenteritis
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    3 / 200 (1.50%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Cellulitis
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Systemic viral infection
    alternative dictionary used: MedDRA 23.0
         subjects affected / exposed
    1 / 200 (0.50%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 2%
    Non-serious adverse events
    		 Tetravalent Dengue Vaccine (TDV) 0.5 mL
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    66 / 200 (33.00%)
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    29 / 200 (14.50%)
         occurrences all number
    33
    Upper respiratory tract infection
         subjects affected / exposed
    20 / 200 (10.00%)
         occurrences all number
    21
    Gastroenteritis
         subjects affected / exposed
    12 / 200 (6.00%)
         occurrences all number
    13
    Systemic viral infection
         subjects affected / exposed
    9 / 200 (4.50%)
         occurrences all number
    9
    Pneumonia
         subjects affected / exposed
    8 / 200 (4.00%)
         occurrences all number
    9
    Conjunctivitis
         subjects affected / exposed
    4 / 200 (2.00%)
         occurrences all number
    4

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 07 05:53:00 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA